View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2017	Mar. 07, 2018	Jun. 30, 2017
Document And Entity Information
Entity Registrant Name	Imprimis Pharmaceuticals, Inc.
Entity Central Index Key	0001360214
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 59,000,000
Entity Common Stock, Shares Outstanding		20,777,629
Trading Symbol	IMMY
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2017

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 4,019	$ 8,853
Restricted cash and short-term investments	200	200
Accounts receivable, net	1,529	2,921
Inventories	2,249	1,841
Prepaid expenses and other current assets	714	938
Note receivable, current portion	95
Total current assets	8,806	14,753
Property, plant and equipment, net	6,215	7,295
Intangible assets, net	2,860	2,972
Investment in Eton Pharmaceuticals	3,507
Note receivable, less current portion	302
Goodwill	2,227	2,227
TOTAL ASSETS	23,917	27,247
Current liabilities
Accounts payable and accrued expenses	3,885	3,538
Accrued payroll and related liabilities	1,209	1,638
Deferred revenue and customer deposits	29	91
Current portion of deferred acquisition obligation and accrued interest	53	207
Current portion of note payable, net of unamortized debt discount		3,973
Current portion of capital lease obligations, net of unamortized discount	598	458
Total current liabilities	5,774	9,905
Capital lease obligations, net of current portion and unamortized discount	720	1,318
Deferred acquisition obligation, net of current portion		52
Accrued expenses, net of current portion	800	667
Deferred tax liability		936
Note payable and paid-in-kind interest, net of unamortized debt discount and current portion	14,008	7,937
TOTAL LIABILITIES	21,302	20,815
STOCKHOLDERS' EQUITY
Preferred stock, $0.001 par value, 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2017 and 2016
Common stock, $0.001 par value, 90,000,000 shares authorized, 20,623,129 and 18,627,915 shares issued and outstanding at December 31, 2017 and 2016, respectively	21	19
Additional paid-in capital	91,430	83,264
Accumulated deficit	(88,836)	(76,851)
TOTAL STOCKHOLDERS' EQUITY	2,615	6,432
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 23,917	$ 27,247

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	90,000,000	90,000,000
Common stock, shares issued	20,623,129	18,627,915
Common stock, shares outstanding	20,623,129	18,627,915

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenues:
Sales, net	$ 26,684	$ 19,927
License revenues	90	15
Total revenues	26,774	19,942
Cost of sales	(13,505)	(9,831)
Gross profit	13,269	10,111
Operating expenses:
Selling and marketing	7,059	7,382
General and administrative	17,960	17,569
Research and development	413	739
Impairment of long-lived assets		303
Total operating expenses	25,432	25,993
Loss from operations	(12,163)	(15,882)
Other income (expense):
Interest expense, net	(3,026)	(2,774)
Early extinguishment of debt	(884)	(1,966)
Change in fair value of derivative liabilities		(113)
Investment loss from Eton Pharmaceuticals	(2,218)
Gain on deconsolidation of Eton Pharmaceuticals	5,725
Loss on sale and disposal of assets	(354)
Other income, net		1,537
Total other expense, net	(757)	(3,316)
Loss before income taxes	(12,920)	(19,198)
Income tax benefit	935	111
Net loss	$ (11,985)	$ (19,087)
Basic and diluted net loss per share of common stock	$ 0.60	$ (1.50)
Weighted average number of shares of common stock outstanding, basic and diluted	20,027,712	12,743,184

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2015	$ 10	$ 56,369	$ (57,764)	$ (1,385)
Balance, share at Dec. 31, 2015	9,755,678
Exercise of stock options		55		55
Exercise of stock options, shares	15,000
Issuance of common stock upon vesting of RSUs, net of tax withholding	$ 1	(144)		(143)
Issuance of common stock upon vesting of RSUs, net of tax withholding , shares	132,367
Registered public offering sale of stock, net of offering costs	$ 3	11,085		11,088
Registered public offering sale of stock, net of offering costs, shares	3,335,000
Sale of stock, net of costs (ATM)		212		212
Sale of stock, net of costs (ATM), shares	57,042
Private placement, issuance of stock and warrants at $1.915 per unit, net of costs, in December 2016	$ 5	9,212		9,217
Private placement, issuance of stock and warrants at $1.915 per unit, net of costs, in December 2016, shares	5,257,828
Stock-based payment for deferred acquisition obligation		302		302
Stock-based payment for deferred acquisition obligation, shares	75,000
Derivative liabilities in connection with convertible note and modification of warrants to purchase common stock issued in connection with note payable		2,362		2,362
Derivative liabilities in connection with convertible note and modification of warrants to purchase common stock issued in connection with note payable, shares
Stock-based compensation expense		3,811		3,811
Net loss			(19,087)	(19,087)
Balance at Dec. 31, 2016	$ 19	83,264	(76,851)	6,432
Balance, share at Dec. 31, 2016	18,627,915
Registered public offering sale of stock, net of offering costs	$ 1	2,939		2,940
Registered public offering sale of stock, net of offering costs, shares	1,312,500
Sale of stock, net of costs (ATM)	$ 1	1,123		1,124
Sale of stock, net of costs (ATM), shares	557,714
Stock-based compensation expense		2,883		2,883
Exercise of warrants		179		179
Exercise of warrants, shares	100,000
Stock-based payment for services provided		60		60
Stock-based payment for services provided, shares	25,000
Relative fair value of warrants to purchase common stock issued in connection with note payable		982		982
Net loss			(11,985)	(11,985)
Balance at Dec. 31, 2017	$ 21	$ 91,430	$ (88,836)	$ 2,615
Balance, share at Dec. 31, 2017	20,623,129

Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016	Mar. 16, 2016
Statement of Stockholders' Equity [Abstract]
Issuance of stock and warrants price per share	$ 1.915	$ 1.915	$ 3.60

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (11,985)	$ (19,087)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property, plant and equipment	1,401	1,055
Amortization of intangible assets	364	351
Non-cash gain on contingent acquisition obligation		(83)
Deferred income taxes	(935)	(111)
Amortization of debt issuance costs and discount	978	970
Debt extinguishment	884	1,966
Paid-in-kind interest added to principal of note payable		203
Gain on deconsolidation of Eton Pharmaceuticals	(5,725)
Investment loss from Eton Pharmaceuticals	2,218
Loss on sale and disposal of assets	354
Change in fair value of derivative liabilities		113
Impairment of long-lived assets		303
Stock-based compensation	2,943	3,673
Issuance of warrant related to litigation settlement		115
Changes in assets and liabilities:
Accounts receivable	1,392	(2,081)
Inventories	(821)	(429)
Prepaid expenses and other current assets	274	(152)
Accounts payable and accrued expenses	346	1,515
Accrued payroll and related liabilities	(429)	438
Deferred revenue and customer deposits	(62)	26
NET CASH USED IN OPERATING ACTIVITIES	(8,803)	(11,215)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds on sale of assets	113
Payments on Pharmacy Creations contingent acquisition obligation		(100)
Investment in restricted marketable securities		(50)
Investment in patent and trademark assets	(252)	(252)
Purchase of Klarity license	(50)
Purchases of property, plant and equipment	(772)	(6,887)
NET CASH USED IN INVESTING ACTIVITIES	(961)	(7,289)
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on capital lease obligations	(626)	(267)
Net proceeds from public equity offering	2,940	11,088
Net proceeds from private placement equity offering		9,217
Payments on Park deferred acquisition obligation	(206)	(195)
Proceeds from SWK debt, net of costs	15,518
Principal payments, exit fee and other costs of LSAF debt	(13,999)
Proceeds from convertible note payable, net of issuance costs		2,772
Proceeds from Essex leaseback, net of issuance costs		1,933
Net proceeds from ATM sales of common stock	1,124	212
Net proceeds from exercise of warrants and stock options, net of taxes remitted for RSU's	179	(88)
NET CASH PROVIDED BY FINANCING ACTIVITIES	4,930	24,672
NET CHANGE IN CASH AND CASH EQUIVALENTS	(4,834)	6,168
CASH AND CASH EQUIVALENTS, beginning of period	8,853	2,685
CASH AND CASH EQUIVALENTS, end of period	4,019	8,853
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes	9	9
Cash paid for interest	1,543	1,366
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Fair value of embedded conversion feature recorded as debt discount and derivative liability		2,322
Reclassification of the fair value of the embedded conversion feature derivative liability to additional paid-in capital upon closing of the public equity offering		2,646
Reclassification of the fair value of the LSAF warrant from additional paid-in capital to derivative liability		675
Reclassification of the fair value of the LSAF warrant derivative liability to additional paid-in capital upon closing of the public equity offering		464
Reduction in value of warrant in connection with debt extinguishment		73
Issuance of common stock to settle contingent acquisition obligation related to the purchase of PC		302
Issuance of stock options for consulting services included in accounts payable and accrued expenses		23
Final fee on note payable recorded as debt discount and included in accrued expenses	800
Estimated relative fair value of warrants issued in connection with note payable	982
Purchase of property, plant and equipment included in accounts payable and accrued expenses		81
Note receivable in connection with sale of assets	$ 410

Organization

12 Months Ended

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

NOTE 1. ORGANIZATION

Imprimis Pharmaceuticals, Inc. (together with its subsidiaries, unless the context indicates or otherwise requires, the “Company” or “Imprimis”) is an ophthalmology-focused pharmaceutical company specialized in the development, production and sale of innovative medications that offer unique competitive advantages and serve unmet needs in the marketplace. The Company is committed to its mission of delivering high-quality novel medications to physicians and patients at affordable prices. Imprimis operates its business through several subsidiaries: ImprimisRx, a leading ophthalmology focused compounding business; Park Compounding, a custom compounding business focused on patient specific orders; and Surface Pharmaceuticals, Inc., an ocular surface disease-focused 505(b)(2) specialty pharmaceutical subsidiary. The Company also own a passive interest, with royalty stakes on certain drug candidates, in Eton Pharmaceuticals, Inc. (or “Eton”), a specialty pharmaceutical business utilizing the 505(b)(2) pathway, which Imprimis spun-out in 2017

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Imprimis has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its wholly and majority owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among others, allowance for doubtful accounts and contractual adjustments, realizability of inventories, valuation of deferred taxes, goodwill and intangible assets, recoverability of long-lived assets and goodwill, valuation of contingent acquisition obligations and deferred acquisition obligations, valuation of notes payable and derivative liabilities, and valuation of stock-based transactions with employees and non-employees. Actual results could differ from those estimates.

Liquidity

The Company has incurred significant operating losses and negative cash flows from operations since its inception. The Company incurred net losses of $11,985 and $19,087 for the years ended December 31, 2017 and 2016, respectively, and had an accumulated deficit of $88,836 and $76,851 as of December 31, 2017 and 2016, respectively. In addition, the Company used cash in operating activities of $8,803 and $11,215 for the years ended December 31, 2017 and 2016, respectively.

While there is no assurance, the Company believes its existing cash resources and restricted cash of approximately $4,219 at December 31, 2017, along with proceeds from the Sales Agreement (see Note 13) will be sufficient to sustain the Company’s planned level of operations for at least the next twelve months. However, estimates of operating expenses and working capital requirements could be incorrect, and the Company could use its cash resources faster than anticipated. Further, some or all of the ongoing or planned activities may not be successful and could result in further losses.

The Company may seek to increase liquidity and capital resources by one or more of the following which may include, but are not limited to: the sale of assets and/or businesses, obtaining financing through the issuance of equity, debt, or convertible securities; and working to increase revenue growth through sales. There is no guarantee that the Company will be able to obtain capital when needed on terms it deems as acceptable, or at all.

Revenue Recognition and Deferred Revenue

The Company recognizes revenues when all of the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured.

Product Revenues

Determination of criteria (3) and (4) is based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Estimated returns and allowances and other adjustments are provided for in the same period during which the related sales are recorded. The Company will defer any revenues received for a product that has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered and no refund will be required.

License Revenues

License arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple element arrangements.

Non-refundable fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company’s performance under the other elements of the arrangement. In addition, if the Company’s continued involvement is required, through research and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term.

Cost of Sales

Cost of sales includes direct and indirect costs to manufacture formulations and other products sold, including active pharmaceutical ingredients, personnel costs, packaging, storage, royalties (see Note 17), shipping and handling costs and the write-off of obsolete inventory.

Research and Development

The Company expenses all costs related to research and development as they are incurred. Research and development expenses consist of expenses incurred in performing research and development activities, including salaries and benefits, other overhead expenses, and costs related to clinical trials, contract services and outsourced contracts.

Debt Issuance Costs and Debt Discount

Debt issuance costs and the debt discount are recorded net of notes payable and capital lease obligations in the consolidated balance sheets. Amortization expense of debt issuance costs and the debt discount is calculated using the effective interest method over the term of the debt and is recorded in interest expense in the accompanying consolidated statements of operations.

Intellectual Property

The costs of acquiring intellectual property rights to be used in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where we have identified an alternative future use for the acquired rights. Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks become more certain (see Goodwill and Intangible Assets). The Company began capitalizing certain costs associated with acquiring intellectual property rights during 2015, if costs are not capitalized they are expensed as incurred.

Income Taxes

As part of the process of preparing the Company’s consolidated financial statements, the Company must estimate the actual current tax liabilities and assess permanent and temporary differences that result from differing treatment of items for tax and accounting purposes. The temporary differences result in deferred tax assets and liabilities, which are included within the consolidated balance sheets. The Company must assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not more likely than not, a valuation allowance must be established which reduces the amount of deferred tax assets recorded on the consolidated balance sheets. To the extent the Company establishes a valuation allowance or increase or decrease this allowance in a period, the impact will be included in income tax expense in the consolidated statement of operations.

The Company accounts for income taxes under the provisions of Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) 740, “Income Taxes”, or ASC 740. As of December 31, 2017, and 2016, there were no unrecognized tax benefits included in the consolidated balance sheets that would, if recognized, affect the effective tax rate. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties in its consolidated balance sheets at December 31, 2017 and 2016, and has not recognized interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2017 and 2016. The Company is subject to taxation in the United States, California and New Jersey. The Company’s tax years since 2000 may be subject to examination by the federal and state tax authorities due to the carryforward of unutilized net operating losses.

Cash and Cash Equivalents

Cash equivalents include short-term, highly liquid investments with maturities of three months or less at the time of acquisition.

Concentrations of Credit Risk

The Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance Corporation (“FDIC”) provides basic deposit coverage with limits up to $250 per owner. At December 31, 2017, the Company had approximately $3,969 in cash deposits in excess of FDIC limits.

Accounts Receivable

Accounts receivable are stated net of allowances for doubtful accounts and contractual adjustments. The accounts receivable balance primarily includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental agencies), but for which payment has not been received. Charges to bad debt are based on both historical write-offs and specifically identified receivables. Contractual adjustments are determined by the amount expected to be collected from third-party providers. Accounts receivable are presented net of allowances for doubtful accounts and contractual adjustments in the amount of $275 and $422 as of December 31, 2017 and 2016, respectively.

Inventories

Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective markets compared with historical cost. Write-downs of inventories are considered to be permanent reductions in the cost basis of inventories.

The Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf life of products and active pharmaceutical ingredients on hand. The Company establishes reserves for excess and obsolete inventories as required based on its analyses.

Investment in Eton Pharmaceuticals, Inc.

In April 2017, the Company formed Eton Pharmaceuticals, Inc. (“Eton”) as a wholly owned subsidiary. In June 2017, Eton entered into and closed on definitive stock purchase agreements with accredited investors for the purchase of Eton’s Series A Preferred Stock that resulted in net proceeds to Eton, after deducting placement agent fees and other expenses, of approximately $18,000. At the time of closing, the Company lost voting and ownership control of Eton and it ceased consolidating Eton’s financial statements. At the time of deconsolidation, the Company recorded a gain of $5,725 and adjusted the carrying value in Eton to reflect the increased valuation of Eton and the Company’s new ownership percent in accordance with ASC 810-10-40-4(c), Consolidation.

The Company owns 3,500,000 common shares (approximately 27% issued and outstanding equity interest as of December 31, 2017) of Eton and, uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Eton. Under this method, the Company recognizes earnings and losses of Eton in its financial statements and adjusts the carrying amount of its investment in Eton accordingly. The Company’s share of earnings and losses are based on the shares of common stock and in-substance common stock of Eton held by the Company. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2017, the Company recorded equity in net loss of Eton of $2,218. As of December 31, 2017, the carrying value of the Company’s investment in Eton was $3,507.

Property, Plant and Equipment

Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful life of the asset. Leasehold improvements and capital lease equipment are amortized over the estimated useful life or remaining lease term, whichever is shorter. Computer software and hardware and furniture and equipment are depreciated over three to five years.

Business Combinations

The Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially with respect to intangible assets, estimated contingent consideration payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the intangible assets the Company has acquired or may acquire in the future include but are not limited to:

	●	future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and

	●	discount rates utilized in valuation estimates.

Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate.

Goodwill and Intangible Assets

Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks become more certain. At that time, the Company capitalizes third-party legal costs and filing fees associated with obtaining and prosecuting claims related to its patents and trademarks. Once the patents have been issued, the Company amortizes these costs over the shorter of the legal life of the patent or its estimated economic life, generally 20 years, using the straight-line method. Trademarks are an indefinite life intangible asset and are assessed for impairment based on future projected cash flows as further described below.

The Company reviews its goodwill and indefinite-lived intangible assets for impairment as of January 1 of each year and when an event or a change in circumstances indicates the fair value of a reporting unit may be below its carrying amount. Events or changes in circumstances considered as impairment indicators include but are not limited to the following:

	●	significant underperformance of the Company’s business relative to expected operating results;

	●	significant adverse economic and industry trends;

	●	significant decline in the Company’s market capitalization for an extended period of time relative to net book value; and

	●	expectations that a reporting unit will be sold or otherwise disposed.

The goodwill impairment test consists of a two-step process as follows:

Step 1. The Company compares the fair value of each reporting unit to its carrying amount, including the existing goodwill. The fair value of each reporting unit is determined using a discounted cash flow valuation analysis. The carrying amount of each reporting unit is determined by specifically identifying and allocating the assets and liabilities to each reporting unit based on headcount, relative revenues or other methods as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its fair value, an indication exists that the reporting unit’s goodwill may be impaired and the Company then performs the second step of the impairment test. If the fair value of a reporting unit exceeds its carrying amount, no further analysis is required.

Step 2. If further analysis is required, the Company compares the implied fair value of the reporting unit’s goodwill, determined by allocating the reporting unit’s fair value to all of its assets and its liabilities in a manner similar to a purchase price allocation, to its carrying amount. If the carrying amount of the reporting unit’s goodwill exceeds its fair value, an impairment loss will be recognized in an amount equal to the excess.

Impairment of Long-Lived Assets

Long-lived assets, such as property, plant and equipment, purchased intangibles subject to amortization and patents and trademarks, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the consolidated balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated balance sheet, if material.

In September 2016, the Company decided to cease operations at its Texas facility, and began winding down the operations. Based on current projections regarding future cash flows of the Texas facility and the related subsidiary, the evaluation resulted in an impairment of $64 related to intangible assets and $239 related to goodwill, recorded to impairment of long-lived assets on the consolidated statements of operations during the year ended December 31, 2016. During the year ended December 31, 2017, the Company did not recognize any impairment of its long-lived assets (See Note 7).

Third Party Billing and Collection Agreements

In connection with its acquisition of Park, the Company entered into a billing and collection agreement with a third party to assist in the billing and collection of workers’ compensation claims. Under the terms of the agreement, the Company is obligated to pay a fixed fee to the third party equal to 55% of the amounts billed and collected under the workers’ compensation claims. The Company accrues for such fees in accounts payable and accrued expenses in the accompanying consolidated balance sheets. Total billing and collection management expense under this agreement for the years ended December 31, 2017 and 2016 was $0 and $55, respectively, and is included in selling and marketing expenses in the accompanying consolidated statements of operations. The amount due under the agreement as of December 31, 2017 and 2016 was $41 and $73, respectively.

Deferred Rent

The Company accounts for rent expense related to its operating leases by determining total minimum rent payments on the leases over their respective periods and recognizing the rent expense on a straight-line basis. The difference between the actual amount paid and the amount recorded as rent expense in each fiscal year and interim periods within each fiscal year is recorded as an adjustment to deferred rent (see Note 10).

Fair Value Measurements

Fair value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels:

●	Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.
●	Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
●	Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.

At December 31, 2017 and 2016, the Company did not have any financial assets or liabilities that are measured on a recurring basis. The Company’s financial instruments included cash and cash equivalents, restricted short-term investments, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred revenue and customer deposits, deferred acquisition obligations, notes payable and capital leases. The carrying amount of these financial instruments, except for deferred acquisition obligations, notes payable and capital leases, approximates fair value due to the short-term maturities of these instruments. The Company’s restricted short-term investments are carried at amortized cost, which approximates fair value. Based on borrowing rates currently available to the Company, the carrying values of the deferred acquisition obligations, notes payable and capital leases, approximate their respective fair values.

Derivative Instruments

The Company accounts for free-standing derivative instruments and hybrid instruments that contain embedded derivative features as either assets or liabilities in the consolidated balance sheets and are measured at fair value with gains or losses recognized in earnings. Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and are recognized at fair value with changes in fair value recognized as either a gain or loss in earnings. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument.

The Company estimates the fair value of derivative instruments and hybrid instruments using various techniques (and combinations thereof) that are considered to be consistent with the objective of measuring fair value. In selecting the appropriate technique, the Company considers, among other factors, the nature of the instrument, the market risks that it embodies and the expected means of settlement. The Company generally uses the Black-Scholes-Merton option pricing model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. Estimating the fair value of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. Increases in the trading price of the Company’s common stock and increases in fair value during a given financial quarter result in the application of non-cash derivative expense. Conversely, decreases in the trading price of the Company’s common stock and decreases in fair value during a given financial quarter would result in the application of non-cash derivative income.

Stock-Based Compensation

All stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units (“RSUs”) and restricted stock, are recognized in the consolidated financial statements based upon their estimated fair values. The Company uses the Black-Scholes-Merton option pricing model and Monte Carlo Simulation to estimate the fair value of stock-based awards. The estimated fair value is determined at the date of grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates.

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows FASB guidance. As such, the value of the applicable stock-based compensation is periodically remeasured and income or expense is recognized during the vesting terms of the equity instruments. The measurement date for the estimated fair value of the equity instruments issued is the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the estimated fair value of the equity instrument is primarily recognized over the term of the consulting agreement. According to FASB guidance, an asset acquired in exchange for the issuance of fully vested, nonforfeitable equity instruments should not be presented or classified as an offset to equity on the grantor’s balance sheet once the equity instrument is granted for accounting purposes. Accordingly, the Company records the estimated fair value of nonforfeitable equity instruments issued for future consulting services as prepaid stock-based consulting expenses in its consolidated balance sheets.

Basic and Diluted Net Loss per Common Share

Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options and warrants, outstanding during the period.

Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents (using the treasury stock and “if converted” method) from deferred acquisition obligations, stock options, unvested RSUs, warrants and convertible notes were 9,980,454 and 9,162,259 at December 31, 2017 and 2016, respectively, and are excluded from the calculation of diluted net loss per share for all periods presented because the effect is anti-dilutive. Included in the basic and diluted net loss per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying these vested RSUs at December 31, 2017 and 2016 was 137,067 and 80,245, respectively,

The following table shows the computation of basic and diluted net loss per share of common stock for the years ended December 31, 2017 and 2016:

	For the Year Ended December 31, 2017			For the Year Ended December 30, 2016

Numerator – net loss	$	(11,985	)	$	(19,087	)
Denominator – weighted average
number of shares outstanding, basic and diluted		20,027,712			12,743,184
Net loss per share, basic and diluted	$	(0.60	)	$	(1.50	)

Recently Adopted Accounting Pronouncements

In March 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which addresses certain aspects of accounting for share-based payment award transactions. The Company adopted this standard on January 1, 2017. The adoption did not have a material impact on the Company’s financial position, results of operations and cash flows. Prior periods were not recast.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory, which requires entities to measure most inventory “at the lower of cost and net realizable value (“NRV”),” thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market. Under the new guidance, inventory is “measured at the lower of cost and net realizable value,” which eliminates the need to determine replacement cost and evaluate whether it is above the ceiling (NRV) or below the floor (NRV less a normal profit margin). The guidance defines NRV as the “estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.” The Company adopted this standard on January 1, 2017. The adoption did not have a material impact on the Company’s financial position, results of operations and cash flows. Prior periods were not recast.

Recently Issued Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers and has subsequently issued a number of amendments to ASU 2014-09. This updated guidance supersedes the current revenue recognition guidance, including industry-specific guidance. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard’s stated core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASU 2014-09 includes provisions within its five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.

The new standard will be effective for the Company beginning January 1, 2018 and permits two methods of adoption: the full retrospective method, which requires the standard to be applied to each prior period presented, or the modified retrospective method, which requires the cumulative effect of adoption to be recognized as an adjustment to opening retained earnings in the period of adoption. The Company will adopt the standard using the modified retrospective method.

The Company has completed an analysis of existing contracts with its customers and assessed the differences in accounting for such contracts under ASU 2014-09 compared with current revenue accounting standards. Based on its review of current customer contracts, the Company does not expect the implementation of ASU 2014-09 to have a material quantitative impact on its consolidated financial statements as the timing of revenue recognition for product sales is not expected to significantly change. In limited instances, the Company may recognize revenue earlier than under the current standard. Under certain licensing arrangements that the Company has considered, there may be times the Company may defer certain revenue where the price pursuant to the underlying customer arrangement is not fixed and determinable. Under the new standard, such customer arrangements will be accounted for as variable consideration, which may result in revenue being recognized earlier provided the Company can reliably estimate the ultimate price expected to be realized from the customer. In addition, the Company does not expect a material effect for any adjustments to retained earnings upon adoption of the standard on January 1, 2018. Adoption of the new standard will also result in additional revenue-related disclosures in the footnotes to the Company’s consolidated financial statements.

In January 2016, the FASB issued ASU 2016-01, Financial Instruments: Recognition and Measurement of Financial Assets and Financial Liabilities, which addresses certain aspects of recognition, measurement, presentation and disclosure of financial statements. This guidance will be effective in the first quarter of fiscal year 2019 and early adoption is not permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.

In February 2016, the FASB issued new lease accounting guidance in ASU No. 2016-02, Leases (Topic 842). This new guidance was initiated as a joint project with the International Accounting Standards Board to simplify lease accounting and improve the quality of and comparability of financial information for users. This new guidance would eliminate the concept of off-balance sheet treatment for “operating leases” for lessees for the vast majority of lease contracts. Under ASU No. 2016-02, at inception, a lessee must classify all leases with a term of over one year as either finance or operating, with both classifications resulting in the recognition of a defined “right-of-use” asset and a lease liability on the balance sheet. However, recognition in the income statement will differ depending on the lease classification, with finance leases recognizing the amortization of the right-of-use asset separate from the interest on the lease liability and operating leases recognizing a single total lease expense. Lessor accounting under ASU No. 2016-02 would be substantially unchanged from the previous lease requirements under GAAP. ASU No. 2016-02 will take effect for public companies in fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted and for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, lessees and lessors must apply a modified retrospective transition approach. During the year ended December 31, 2017, the Company evaluated this new accounting standard and engaged professionals in the new lease accounting implementation to assist in determining the effect of the new standard as of January 1, 2018 with respect to the Company’s real estate leases. The Company currently has three real estate leases and evaluated each of these leases in accordance with the new lease accounting standard under ASC Topic 842. As of January 1, 2018, the Company estimates that the right of use asset to be recorded on its consolidated balance sheet would be approximately $2,400 and that the related lease liability would be approximately $3,000 related to operating leases. The difference between the right of use asset and related lease liability is predominantly deferred rent and other related lease expenses under the new lease accounting standard. The Company will continue this effort with respect to equipment leases and any other leases contemplated under Topic 842 in a manner to be appropriately prepared for its implementation on or before January 1, 2019.

In August 2016, the FASB issued ASU 2016-18, Statement of Cash Flows: Classification Restricted Cash, which requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for reporting periods beginning after December 15, 2017 with early adoption permitted. The Company expects the implementation of this standard to have an impact on the Company’s consolidated financial statements and related disclosures as the Company had restricted cash on our balance sheet of $200 as of December 31, 2017, and currently do not present the amount as a cash equivalent in our consolidated statements of cash flows.

In January 2017, the FASB issued ASU 2017-01, Business Combinations, Clarifying the Definition of a Business, which revises the definition of a business and provides new guidance in evaluating when a set of transferred assets and activities is a business. ASU 2017-01 is effective for reporting periods beginning after December 15, 2017 with early adoption permitted. The Company does not expect the ASU 2017-01 to have a material impact on the Company’s financial position, results of operations and cash flows.

In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other. This guidance simplifies the accounting for goodwill impairment for all entities by requiring impairment charges to be based on the first step in the current two-step impairment test under ASC 350. The updated standard eliminates the requirement to calculate a goodwill impairment charge using Step 2. If a reporting unit’s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. ASU 2017-04 is effective for reporting periods beginning after December 31, 2019 on a prospective basis, and early adoption is permitted. The Company does not expect ASU 2017-04 to have a material effect on the Company’s financial position, results of operations and cash flows.

In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation: Scope of Modification Accounting. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting under Topic 718. An entity should account for effects of a modification unless all of the following are met: (1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; (3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The amendments in this update are effective for all entities for annual periods and interim periods within those annual periods, beginning after December 15, 2017, which for the Company means January 1, 2018. Early adoption is permitted, including adoption in any interim period for public business entities for reporting periods for which financial statements have not yet been issued. The Company does not expect the adoption of ASU 2017-09 to have a material effect on the Company’s financial position, results of operations and cash flows.

Investment in Eton Pharmaceuticals, Inc. and Agreements - Related Party Transactions

12 Months Ended

Dec. 31, 2017

Investment in Eton Pharmaceuticals, Inc. and Agreements - Related Party Transactions

NOTE 3. INVESTMENT IN ETON PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS

In May 2017, the Company entered into two asset purchase and license agreements (the “Eton License Agreements”) with its previously wholly owned subsidiary, Eton Pharmaceuticals, Inc. Pursuant to the terms of the Eton License Agreements, the Company assigned and licensed to Eton certain intellectual property and related rights to develop, formulate, make, sell, and sub-license formulations of synthetic corticotropin and injectable pentoxifylline (collectively, the “Eton Products”). Eton is required to make royalty payments to the Company of six percent (6%) of net sales of the Eton Products while any patent rights remain outstanding and then three percent (3%) of net sales in the event patent claims are not issued. In addition, Eton is required to make certain milestone payments to the Company including payments of $50 upon initial patent issuances for each Eton Product. The Eton License Agreements were conditioned upon Eton receiving net proceeds of the sale of its equity securities of not less than $10,000, which occurred in June 2017. See also Note 2, under the subheading Investment in Eton Pharmaceuticals, Inc.

On May 1, 2017, the Company and Eton entered into a Management Services Agreement (the “MSA”), whereby the Company provided to Eton certain administrative services and support, including bookkeeping, web services and human resources related activities, and Eton will pay the Company a monthly amount of $10. A 30-day notice of termination was delivered to the Company on August 29, 2017. Eton paid the Company $40 for services under the MSA.

As of December 31, 2017, the Company was due $50 from Eton for amounts due related a milestone payment under the Eton Licenses Agreement for the issuance of certain patent rights, this amount is included in license revenues and other current assets on the accompanying consolidated financial statements.

The Company owns approximately 27% of the voting interests in Eton. The Company’s Chief Executive Officer, Mark L. Baum, is a director of Eton, and several employees of the Company (including Mr. Baum and the Company’s Chief Financial Officer, Andrew R. Boll) have entered into consulting agreements with Eton.

The unaudited condensed results of operations information of Eton is summarized below (in thousands):

	From the period beginning April 27, 2017 (inception) to December 31, 2017
Revenues, net	$	-
Loss from operations		8,036
Net loss	$	(8,036	)

The unaudited condensed balance sheet information of Eton is summarized below (in thousands):

	At December 31, 2017
Current assets	$	13,440
Total assets		13,440

Current liabilities		764
Stockholders’ equity		12,676
Total liabilities and stockholders’ equity	$	13,440

Restricted Cash

12 Months Ended

Dec. 31, 2017

Cash and Cash Equivalents [Abstract]

Restricted Cash

NOTE 4. RESTRICTED CASH

The restricted cash at December 31, 2017 and 2016 consisted of funds held in a money market account. At December 31, 2017 and 2016, the restricted cash was recorded at amortized cost, which approximates fair value.

At December 31, 2017 and 2016, the funds held in a money market account of $200 were classified as a current asset. The money market account funds are required as collateral as additional security for the Company’s New Jersey facility lease.

Inventories

12 Months Ended

Dec. 31, 2017

Inventory Disclosure [Abstract]

Inventories

NOTE 5. INVENTORIES

Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of December 31, 2017 and 2016 was as follows:

	December 31, 2017		December 31, 2016

Raw materials	$	956	$	669
Finished goods		1,293		1,172
Total inventories	$	2,249	$	1,841

Prepaid Expenses and Other Current Assets

12 Months Ended

Dec. 31, 2017

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses and Other Current Assets

NOTE 6. PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consisted of the following:

	December 31, 2017		December 31, 2016
Prepaid insurance	$	164	$	315
Other prepaid expenses		426		517
Deposits and other current assets		124		106
Total prepaid expenses and other current assets	$	714	$	938

Asset Sales and Note Receivable

12 Months Ended

Dec. 31, 2017

Asset Sales And Note Receivable

Asset Sales and Note Receivable

NOTE 7. ASSET SALES AND NOTE RECEIVABLE

On June 27, 2017, the Company entered into an Asset Purchase Agreement (the “PA Agreement”) with Creative Pharmacy Solutions Central, LLC (the “Buyers”), which closed in July 2017. Under the terms of the PA Agreement, the Company sold substantially all its assets associated with its sinus related business, including but not limited to, certain intellectual property rights, trademarks, copyrights, inventories, equipment, customer lists, databases, permits, licenses, and assignment of the Company’s lease obligation for its Pennsylvania based pharmacy (the “PA Assets”), for a total purchase price of approximately $450.

Under the terms of the PA Agreement, the Buyers, upon closing, paid to the Company an aggregate cash amount of $40. In addition, the Buyers are obligated to pay the remaining $410 pursuant to a note bearing interest at 6% per annum (the “Sellers Note”). The Buyers are required to make forty-eight monthly cash payments to the Company of $10 following the closing, totaling $462; provided however, that the Buyer had the option to make a one-time payment of $365 any time prior to December 31, 2017, and the Company would have waive any remaining amounts due on the Sellers Note. The principal amount of the Sellers Note was also subject to post-closing adjustment through December 31, 2017, if certain criteria were met, however, that period ended and no adjustments were made. There was $400 due under the Sellers Note as of December 31, 2017, which has not yet been paid.

At December 31, 2017, future minimum payments to the Company under its note receivable were as follows:

	Amount
2018	$	135
2019		116
2020		116
2021		77
Total minimum note receivable, including interest		444
Less: amount representing interest income		47
Present value of future minimum note receivable		397
Less: current portion		95
Note receivable net of current portion	$	302

The Company recorded a loss of $69 during the year ended December 31, 2017, related to the sale of the PA Assets.

In June 2017, in a separate transaction, the Company entered into an agreement to sell certain equipment to a third party for amount of $60 and closed the transaction in July 2017. The Company recorded a loss related to equipment of $52 during the year ended December 31, 2017.

Assets sold during the year ended December 31, 2017 consisted of the following:

	December 31, 2017
Inventories	$	413
Furniture and equipment		226
		639
Loss on asset sale		(127	)
Assets sold	$	512

In February 2017, the Company entered into a stock purchase agreement (the “SPA”) with Livernois & London, LLC (“Livernois”). Pursuant to the terms of the SPA, the Company sold to Livernois 100% of the issued and outstanding shares of common stock of its Texas based subsidiary, ImprimisRx TX, Inc. dba ImprimisRx (“Imprimis TX”). The SPA did not transfer to Livernois any of the Company’s rights to intellectual property, products, clients, nor any of its existing business operations. As consideration for the purchase of Imprimis TX, Livernois paid the Company $10 and the Company assigned, and Livernois assumed, the remaining lease obligation totaling $113 for the Texas based facility. The Company recorded a loss of $173 from the sale of Imprimis TX for the year ended December 31, 2017, which is included in the accompanying consolidated statements of operations.

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

NOTE 8. PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment at December 31, 2017 and 2016 consisted of the following:

	December 31, 2017			December 31, 2016
Property, plant and equipment, net;
Computer software and hardware	$	1,239		$	831
Furniture and equipment		377			424
Lab and pharmacy equipment		2,545			2,559
Leasehold improvements		4,810			4,836
		8,971			8,650
Accumulated depreciation and amortization		(2,756	)		(1,355	)
	$	6,215		$	7,295

The Company recorded depreciation and amortization expense of $1,401 and $1,055 during the years ended December 31, 2017 and 2016, respectively.

Intangible Assets and Goodwill

12 Months Ended

Dec. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill

NOTE 9. INTANGIBLE ASSETS AND GOODWILL

The Company’s intangible assets at December 31, 2017 consisted of the following:

	Amortization
	periods			Accumulated						Net
	(in years)	Cost		amortization			Impairment			Carrying value
Patents	17-19 years	$	365	$	(21	)	$	-		$	344
Licenses	20 years		50		-			-			50
Trademarks	Indefinite		276		-			-			276
Customer relationships	3-15 years		2,998		(813	)		(15	)		2,170
Trade name	5 years		16		(9	)		(1	)		6
Non-competition clause	3-4 years		294		(273	)		(20	)		1
State pharmacy licenses	25 years		45		(4	)		(28	)		13
		$	4,044	$	(1,120	)	$	(64	)	$	2,860

Amortization expense for intangible assets for the year ended December 31 was as follows:

	For the		For the
	Year Ended		Year Ended
	December 31, 2017		December 31, 2016
Patents	$	15	$	5
Customer relationships		257		255
Trade name		3		3
Non-competition clause		87		86
State pharmacy licenses		2		2
	$	364	$	351

Estimated future amortization expense for the Company’s intangible assets at December 31, 2017 is as follows:

Years ending December 31,
2018	$	228
2019		225
2020		222
2021		222
2022		222
Thereafter		1,741
	$	2,860

The changes in the carrying value of the Company’s goodwill during the years ended December 31, 2017 and 2016 were as follows:

Balance at January 1, 2016	$	2,466
Impairment of ImprimisRx TX		(239	)
Balance at December 31, 2016	$	2,227
No changes		-
Balance at December 31, 2017	$	2,227

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2017

Payables and Accruals [Abstract]

Accounts Payable and Accrued Expenses

NOTE 10. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses at December 31, 2017 and 2016 consisted of the following:

	December 31, 2017			December 31, 2016
Accounts payable	$	3,241		$	2,999
Deferred rent		388			412
Accrued interest (see Note 11)		256			116
Accrued exit fee for notes payable (see Note 11)		800			667
Building lease liability		-			11
Total accounts payable and accrued expenses		4,685			4,205
Less: Current portion		(3,885	)		(3,538	)
Non-current total accrued expenses	$	800		$	667

Debt

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Debt

NOTE 11. DEBT

LSAF Senior Note – 2015

On May 11, 2015, the Company entered into a loan and security agreement (the “Loan Agreement”) with IMMY Funding LLC, an affiliate of Life Sciences Alternative Funding LLC (the “LSAF”), as lender and collateral agent. Pursuant to the terms of the Loan Agreement, as amended in January 2016 and December 2016 (see further description of December 2016 amendment below), LSAF made available to the Company a term loan in the aggregate principal amount of up to $10,000, all of which was drawn on May 11, 2015. The term loan bore interest at a fixed per-annum rate of 12.5% and allowed for 2% of the interest to be paid-in-kind until December 2016. The Company was permitted to pay interest only until June 1, 2017. The Company was required to pay interest, plus repayments of the principal amount of the term loan, in 20 equal monthly installments. All amounts owed under the Loan Agreement, including a final fee of 5% of the aggregate principal amount of the term loan and prepayment fees of up to 1% of the principal balance were due on January 1, 2019. The Company incurred expenses of approximately $1,066 in connection with the Loan Agreement. The final fee and expenses were amortized as interest expense over the term of the debt using the interest method and the related liability of $667 for the final fee, as of December 31, 2016, is included in accrued expenses (see Note 10) in the accompanying consolidated balance sheets.

In connection with the Loan Agreement, the Company issued to LSAF a warrant to purchase up to 125,000 shares of the Company’s common stock, which is exercisable immediately, has an exercise price of $7.85 per share upon issuance and has a term of 10 years. The relative fair value of the warrants was approximately $840 and was estimated using the Black-Scholes-Merton option pricing model with the following assumptions: fair value of the Company’s common stock at issuance of $7.97 per share; ten-year contractual term; 109% volatility; 0% dividend rate; and a risk-free interest rate of 1.25%. The relative fair value of the warrants was recorded as a debt discount, decreasing notes payable and increasing additional paid-in capital on the accompanying consolidated balance sheet. The debt discount is being amortized to interest expense over the term of the debt using the effective interest rate method. As described further, this warrant was amended in January 2016 and December 2016.

Convertible Senior Note and Exchange Agreement – 2016

On January 22, 2016, the Company entered into a note purchase agreement (the “NPA”) with, and issued an 8.00% Convertible Senior Secured Note (“Convertible Note”) in the principal amount of $3,000 to LSAF. Pursuant to the terms of the NPA, on the date thereof, the Company issued the Convertible Note to LSAF and, as consideration therefor, LSAF paid the Company in cash the full principal amount of the Convertible Note. The Company incurred expenses of approximately $228 in connection with the Convertible Note and these expenses were recorded as a debt discount. The debt discount was being amortized as interest expense over the term of the debt using the effective interest rate method.

Pursuant to the terms of the Convertible Note, the Company was obligated to pay interest on the principal amount of the Convertible Note monthly in cash at a fixed per-annum rate of 8.00%, and the Company was obligated to repay the full principal amount of the Convertible Note in cash on May 11, 2021. The Company was permitted to redeem the Convertible Note prior to its maturity at any time on or after March 1, 2018 for cash purchase prices equal to 109% - 105% of the outstanding principal amount of the Convertible Note, depending on the date of redemption. The Convertible Note was initially convertible by the holder at any time into shares of the Company’s common stock at an effective conversion price of approximately $5.90 and subject to anti-dilution adjustment upon the Company’s first equity financing while the Convertible Note is outstanding in which it receives gross proceeds of at least $3,000, if such equity financing is completed at a per share price that is less than the conversion rate of the Convertible Note, and also subject to adjustment upon stock combinations or splits, certain recapitalizations, stock or cash dividends or other distributions of property or equity rights. Additionally, in the event of certain change of control events affecting the Company, the Company may be required, at the option of LSAF, to repurchase the Convertible Note in cash for the greater of 105% of the outstanding principal amount of the Convertible Note or the value of the shares of common stock issuable upon conversion of the Convertible Note. The fair value of the conversion feature was $2,322 and was recorded as a debt discount, decreasing notes payable and increasing additional paid-in capital on the accompanying consolidated balance sheet (see also Note 13). The debt discount is being amortized to interest expense over the term of the debt using the effective interest method.

In connection and concurrently with the execution of the NPA and the issuance of the Convertible Note, the Company and LSAF also entered into an amendment (the “Loan Agreement Amendment”) to the Loan Agreement (see above). The Loan Agreement Amendment modifies the terms of the Loan Agreement in order to eliminate the potential borrowing of a second term loan thereunder and to permit the Company to issue the Convertible Note. Additionally, the Company and LSAF entered into an amendment (the “Warrant Amendment”) to the warrants that were issued to LSAF in connection with the Loan Agreement. The Warrant Amendment modifies the terms of the warrants in order to reduce the exercise price thereof to $5.90 per share, which is consistent with the initial conversion rate of the Convertible Note, and to add an anti-dilution adjustment provision that is consistent with the same such provision in the Convertible Note.

On March 16, 2016, upon the closing of the Offering (see Note 13) and pursuant to the anti-dilution adjustment provisions of the Convertible Note and the Warrant Amendment, the effective conversion price of the Convertible Note was adjusted to approximately $3.60, and the exercise price of the warrants was adjusted to $3.60 per share (see also Note 13 for further accounting discussion of the warrant exercise price and conversion provisions and related derivative liabilities). The warrant was amended again in December 2016, to adjust the exercise price to $1.79 per share, in connection with the Exchange Agreement (described below).

On December 27, 2016, the Company entered into a third amendment (the “Amendment”) to the Loan Agreement with LSAF. Concurrently with entering into and related to the Amendment, the Company and LSAF also entered into an Exchange and Discharge Agreement (the “Exchange Agreement”). The Amendment and Exchange Agreement, among other things, primarily allowed for the Company and LSAF to exchange the Convertible Note for a $3,000 term loan (the “Term B Loan”). The Term B Loan was issued in exchange for, and not funded separately, cancellation and discharge of all indebtedness related to the Convertible Note. Terms, conditions and security interests of the Term B Loan are substantially equal to those of the Loan Agreement. The Amendment also amended certain terms and definitions associated with prepayment, payment schedule, amortization periods and defined the outstanding principal amounts due to LSAF under the Loan Agreement and Term B Loan, including any interest that has been paid in kind of the principal balance, in aggregate, as $13,332. In connection with the Exchange Agreement, during the year ended December 31, 2016, the Company recorded early extinguishment expense of $1,966 for remaining unamortized debt discounts related to the Convertible Note at the time of the Exchange Agreement.

SWK Senior Note and LSAF Payoff – 2017

In July 2017, the Company entered into a term loan and security agreement in the principal amount of $16,000 (the “SWK Loan Agreement” or “SWK Loan”) with SWK Funding LLC and its partners (“SWK”), as lender and collateral agent. The SWK Loan Agreement was fully funded at closing with a five-year term, however, such term may be reduced to four years if certain revenue requirements are not achieved. Concurrently with the funding, the Company utilized a portion of the SWK Loan funds as full payment to an affiliate of LSAF to terminate all amounts due to LSAF in connection with the LSAF related loans (Loan Agreement and Term B Loan). In total, including previously made principal payments, the Company made payments of $13,999 to pay-off the LSAF related loans and expenses, which also included the previously accrued exit fee, interest paid in kind and other expenses related to the payoff. The Company also recorded a loss on early extinguishment of debt during the year ended December 31, 2017 of $884 related to the pay-off.

The SWK Loan bears interest at a variable rate equal to the three-month London Inter-Bank Offered Rate (subject to a minimum of 1.50% and maximum of 3.00%), plus an applicable margin of 10.50%. The SWK Loan Agreement permits the Company to pay interest only on the principal amount loaned thereunder for the first six payments (payments are due on a quarterly basis), which interest-only period may be reduced to four payments if the Company does not meet certain minimum revenue requirements. Following the interest-only period, the Company will be required to pay interest, plus repayments of the principal amount loaned under the SWK Loan Agreement, in quarterly payments, which shall not exceed $750 per quarter. All amounts owed under the SWK Loan Agreement, including a final fee equal to 5% of the aggregate principal amount loaned thereunder, will be due and payable on July 19, 2022, or if certain revenue requirements are not met, July 19, 2021. The Company may elect to prepay all, but not less than all, of the amounts owed under the SWK Loan Agreement prior to the maturity date at any time after July 19, 2019. If certain revenue requirements are not met, the Company may be allowed to prepay the loan from July 19, 2018 to July 19, 2019, provided that a prepayment fee equal to 6% of the principal amount of the loan will also be due. The Company is also obligated under the SWK Loan Agreement to pay for certain expenses incurred by the SWK Lender through and after the date of the SWK Loan Agreement, including certain fees and expenses relating to the preparation and administration of the SWK Loan Agreement. The Company incurred expenses and final fee of approximately $1,282 in connection with the Loan Agreement. The final fee and expenses are being amortized as interest expense over the term of the debt using the effective interest rate method and the related liability of $800 for the final fee is included in accrued expenses (see Note 10) in the accompanying consolidated balance sheet as of December 31, 2017.

In connection with the SWK Loan Agreement, the Company issued to SWK warrants to purchase up to 415,586 shares of the Company’s common stock (the “Lender Warrants”) with an exercise price of $3.08. In August 2017, the Company and SWK amended the warrants, to allow for the purchase up to 615,386 warrants with an exercise price of $2.08. The Lender Warrants are exercisable immediately, and have a term of 7 years. The Lender Warrants are subject to a cashless exercise feature, with the exercise price and number of shares issuable upon exercise subject to change in connection with stock splits, dividends, reclassifications and other conditions. The relative fair value of the Lender Warrants were approximately $982 and was estimated using the Black-Scholes-Merton option pricing model with the following assumptions: fair value of the Company’s common stock at issuance of $2.08 per share; seven-year contractual term; 113.5% volatility; 0% dividend rate; and a risk-free interest rate of 1.77%.

For the years ended December 31, 2017 and 2016, debt discount amortization related to notes payable were $811 and $970, respectively.

Notes payable at December 31, 2017 were as follows:

	December 31, 2017
SWK note	$	16,000
Less: Discount on note		(1,992	)
Less: Current portion		-
Long-term portion	$	14,008

Future minimum payments under notes payable outstanding at December 31, 2017 are as follows:

Year Ending December 31,	Amount
2018	$	1,947
2019		3,657
2020		3,440
2021		3,214
2022		11,201
Total minimum payments		23,459
Less: amount representing interest		(7,459	)
Notes payable, gross	$	16,000

Capital Lease Obligation

12 Months Ended

Dec. 31, 2017

Leases [Abstract]

Capital Lease Obligation

NOTE 12. CAPITAL LEASE OBLIGATION

On August 9, 2016, the Company entered into a commercial lease agreement (the “Lease Agreement”) with Essex Capital Corporation (“Essex”). Pursuant to the terms of the Lease Agreement, the Company sold certain equipment (the “Equipment”) to Essex for a total purchase price of approximately $2,000, which was then leased back to the Company under a thirty-six month term net basis lease with monthly payments of approximately $64. The fair value of equipment sold and then leased under the Lease Agreement totaled approximately $2,000. The lease term may be extended for an additional twelve month period in the event the Company achieves certain financial milestones. The Company has the right to purchase the Equipment from Essex upon the expiration of the Lease Agreement for a purchase price equal to the Equipment’s then fair market value, with such fair market value not to exceed fifteen percent of the original Equipment value on August 9, 2016. If the Equipment is not purchased at the end of the term, the Company may automatically extend the lease on a month-to-month basis or return the Equipment and terminate the Lease Agreement. The Company expects to purchase the Equipment at the end of the term of the lease and has accrued the final payment amount of $300. The Company also incurred expenses of approximately $67 in connection with the Lease Agreement. The issuance costs were recorded as a discount. The discount is being amortized as interest expense over the term of the lease using the effective interest method. The Company used an interest rate of 16.8% for calculation of the present value of the future minimum payments under the Lease Agreement. For the years ended December 31, 2017 and 2016, debt discount amortization related to the Lease Agreement was $167 and $90, respectively, and is included in interest expense in the accompanying consolidated statement of operations.

At December 31, 2017, future payments under the Company’s capital lease were as follows:

	Amount
2018	$	773
2019		751
Total minimum lease payments		1,524
Less: amount representing interest payments		(96	)
Present value of future minimum lease payment		1,427
Less: unamortized discount		(110	)
		1,317
Less: current portion, net of unamortized discount		(598	)
Capital lease obligation net of current portion and unamortized discount	$	720

The value of the equipment under capital leases as of December 31, 2017 and 2016 was $2,070, with related accumulated depreciation of $444 and $293, respectively.

Stockholders' Equity and Stock-based Compensation

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Stockholders' Equity and Stock-based Compensation

NOTE 13. STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION

Common Stock

At December 31, 2017 and 2016, the Company had 90,000,000 shares of common stock, $0.001 par value, authorized.

Issuances During the Year Ended December 31, 2016

In March 2016, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with National Securities Corporation and several other underwriters, under which the Company sold in a firm-commitment public offering (the “Offering”), 3,335,000 shares of the Company’s common stock at $3.60 per share. The Offering closed on March 16, 2016. The Company received net proceeds of $11,088, after deducting the underwriting discount and the offering expenses payable by the Company.

In November 2015, the Company entered into a Controlled Equity Offering^SM sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as agent (“Cantor Fitzgerald”), pursuant to which the Company may offer and sell, from time to time through Cantor Fitzgerald, shares of our common stock having an aggregate offering price as set forth in the Sales Agreement and a related prospectus supplement filed with the Securities and Exchange Commission. The Company agreed to pay Cantor Fitzgerald a cash commission of 3.0% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. The Company sold 57,042 shares of common stock and received net proceeds of $212, after deducting $20 for sales commission and offering expenses, under the Sales Agreement during the year ended December 31, 2016.

In May 2016, we issued 75,000 shares of the Company’s common stock, with a fair value of $302, as a contingent payment related to the acquisition of PC (see Note 17).

In October 2016, the Company issued 16,076 shares of its common stock in connection with RSUs that had been awarded to a non-employee director and had vested, but were not issued and settled until the resignation of the director in September 2016.

In December 2016, the Company issued 116,291 shares of its common stock to its CEO, Mark L. Baum, in connection with 200,000 RSUs that had vested in May 2016. The issuance of common stock was net of 83,709 shares of common stock withheld for payroll tax withholdings totaling $144.

In December 2016, the Company entered into a securities purchase agreement with certain purchasers, which provided for the sale of 5,257,828 Units, with each Unit consisting of one share of common stock of the Company, and one warrant to purchase one share of common stock (the “Investor Warrants”), at a price of $1.915 per Unit for aggregate net proceeds of approximately $9,217 after deducting $852 in placement agent fees and offering expenses (the “PIPE Offering”). The Investor Warrants have an exercise price of $1.79 per share, are non-exercisable for the first six months and will expire three years from the date of issuance. The Company paid National Securities Corporation (the “Placement Agent”), in consideration for its services as placement agent for the PIPE Offering, a cash amount equal to 7.5% of the gross proceeds from the sale of the Units. The Company also issued to the Placement Agent a warrant (the “Agent Warrant”) to purchase up to 210,313 shares of the Company’s common stock. The Agent Warrant was issued on the same terms and conditions of the Investor Warrants.

During the year ended December 31, 2016, the Company issued a total of 15,000 shares of common stock as a result of option exercises. The Company received $55 in cash proceeds for the issuance of the shares of common stock upon the exercise pursuant to exercise provisions of stock options to purchase 15,000 shares of common stock with exercise price of $3.68 per share.

During the year ended December 31, 2017, 24,421 shares of the Company’s common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until the director resigns.

Issuances During the Year Ended December 31, 2017

In March 2017, we entered into securities purchase agreements with two accredited investors, which provided for the sale by the Company of 1,312,500 shares of its common stock, at a price of $2.40 per share (the “Registered Offering”). We received net proceeds of $2,940 after deducting the underwriter discount of 6% of the gross proceeds from the Registered Offering and other related expenses.

In March 2017, the Company issued 25,000 shares of its restricted common stock, with a fair value of $60, as payment for investor relations related services.

In April 2017, the Company issued 100,000 shares of common stock as a result of warrant exercises. The Company received cash proceeds of $179 upon the exercise of the warrants with an exercise price of $1.79.

The Company sold 557,714 shares of common stock and received net proceeds of $1,124, after deducting $35 for sales commission and offering expenses, under the Sales Agreement during the year ended December 31, 2017, leaving an aggregate of $8,040 available for future sales of shares thereunder as of December 31, 2017.

During the year ended December 31, 2017, 56,822 shares of the Company’s common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until the director resigns.

Preferred Stock

At December 31, 2017 and 2016, the Company had 5,000,000 shares of preferred stock, $0.001 par value, authorized and no shares of preferred stock issued and outstanding.

Stock Option Plan

On September 17, 2007, the Company’s Board of Directors and stockholders adopted the Company’s 2007 Incentive Stock and Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended, the “2007 Plan”). The 2007 Plan reached its term in September 2017, and we can no longer issue additional awards under this plan, however, options still outstanding and previously issued under the 2007 Plan will remain outstanding until they are exercised, reach their maturity or are otherwise cancelled/forfeited. On June 13, 2017, the Company’s Board of Directors and stockholders adopted the Company’s 2017 Incentive Stock and Awards Plan (the “2017 Plan” together with the 2007 Plan, the “Plan”). As of December 31, 2017, the 2017 Plan provide for the issuance of a maximum of 2,000,000 shares of the Company’s common stock. The purpose of the Plan is to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons in the Company’s development and financial success. Under the Plan, the Company is authorized to issue incentive stock options intended to qualify under Section 422 of the Internal Revenue Code, non-qualified stock options, restricted stock units and restricted stock. The Plan is administered by the Compensation Committee of the Company’s Board of Directors. The Company had 1,997,500 shares available for future issuances under the 2017 Plan at December 31, 2017.

Stock Options

A summary of stock option activity under the Plan for the year ended December 31, 2017 is as follows:

	Number of shares			Weighted Avg. Exercise Price		Weighted Avg. Remaining Contractual Life		Aggregate Intrinsic Value
Options outstanding - January 1, 2017		2,013,313		$	6.20
Options granted		538,000		$	2.37
Options exercised		-		$	-
Options cancelled/forfeit		(291,334	)	$	4.45
Options outstanding - December 31, 2017		2,259,979		$	5.51		6.11	$	1
Options exercisable		989,664		$	5.74		6.38	$	-
Options vested and expected to vest		2,137,854		$	5.51		6.12	$	1

The aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which would have been received by option holders if all option holders had exercised and immediately sold all options with an exercise price lower than the market price on December 31, 2017, based on the closing price of the Company’s common stock of $1.70 on that date.

During 2017 and 2016, the Company granted stock options to certain employees, directors and consultants. The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms ranging from five to 10 years. Vesting terms for options granted in 2017 and 2016 to employees and consultants typically included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; quarterly vesting over three years. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plan) and in the event of certain modifications to the option award agreement.

The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The expected volatility is based on the historical volatilities of the common stock of the Company and comparable publicly traded companies based on the Company’s belief that it currently has limited relevant historical data regarding the volatility of its stock price on which to base a meaningful estimate of expected volatility. The expected term of options granted was determined in accordance with the “simplified approach,” as the Company has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of 10%. These factors could change in the future, which would affect the determination of stock-based compensation expense in future periods. Utilizing these assumptions, the fair value is determined at the date of grant.

The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees:

	2017			2016
Weighted-average fair value of options granted	$	2.04		$	3.91
Expected terms (in years)		5.81 - 6.11			5.81 - 6.11
Expected volatility		112 - 117	%		101 - 112	%
Risk-free interest rate		1.77 - 2.01	%		1.07 - 1.70	%
Dividend yield		-			-

The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to consultants:

	2016
Weighted-average fair value of options granted	$	6.18
Expected terms (in years)		10
Expected volatility		109	%
Risk-free interest rate		1.06	%
Dividend yield		-

The following table summarizes information about stock options outstanding and exercisable at December 31, 2017:

	Options Outstanding						Options Exercisable
			Weighted
			Average		Weighted				Weighted
			Remaining		Average				Average
	Number		Contractual		Exercise		Number		Exercise
Range of Exercise Prices	Outstanding		Life in Years		Price		Exercisable		Price
$1.47 - $2.60		584,500		8.15	$	2.18		197,997	$	2.35
$3.20 - $4.50		539,906		7.94	$	3.97		286,855	$	3.99
$5.49 - $6.36		106,536		5.61	$	5.95		103,092	$	5.97
$6.64 - $8.99		1,024,007		4.05	$	7.98		396,690	$	8.18
$42.80		5,030		2.62	$	42.80		5,030	$	42.80
$1.47 - $42.80		2,259,979		6.11	$	5.51		989,664	$	5.74

As of December 31, 2017, there was approximately $4,103 of total unrecognized compensation expense related to unvested stock options granted under the Plan. That expense is expected to be recognized over the weighted-average remaining vesting period of 2.5 years. The stock-based compensation for all stock options was $1,672 and $2,159 during the years ended December 31, 2017 and 2016, respectively.

Restricted Stock Units

RSU awards are granted subject to certain vesting requirements and other restrictions, including performance and market based vesting criteria. The grant-date fair value of the RSUs, which has been determined based upon the market value of the Company’s common stock on the grant date, is expensed over the vesting period of the RSUs. Unvested portions of RSUs issued to consultants are remeasured on an interim basis until vesting criteria is met.

Grants During the Year Ended December 31, 2016

In April 2016, the Company granted performance-based RSU awards to its CEO, Mark L. Baum, of up to 1,050,000 performance stock units and to its CFO, Andrew R. Boll, of up to 157,500 performance stock units. The performance stock units will vest on the fifth anniversary of the grant date, subject to Mr. Baum’s and Mr. Boll’s continued employment with the Company, respectively, and may vest earlier if the Company achieves and maintains certain stock price targets during the five-year period following the grant date or upon a change in control if the performance-based equity award is not assumed, continued or substituted for by the acquiring entity. The market-based accelerated vesting criteria are broken into five equal tranches and require that the Company achieve and maintain certain stock price targets ranging from $9 per share to $15 per share during the five-year period following the grant date. These market-based accelerated vesting conditions and share amounts (in aggregate) are set forth below:

Tranche	Number of shares	Target share price
Tranche 1	230,000 shares	$9.00 or greater
Tranche 2	230,000 shares	$10.00 or greater
Tranche 3	230,000 shares	$12.00 or greater
Tranche 4	230,000 shares	$14.00 or greater
Tranche 5	287,500 shares	$15.00 or greater

For each respective tranche to vest the following conditions must be met: (i) the Company’s common stock must have an official closing price at or above the target share price for the respective tranche (each such date, a “Trigger Date”); (ii) during the period that includes the Trigger Date and the immediately following 19 trading days (the “Measurement Period”), the arithmetic mean of the 20 closing prices of the Company’s common stock during the Measurement Period must be at or above the target share price for such tranche; and (iii) with certain limited exceptions, the executive must be in service with the Company through the date of vesting.

Concurrent with the issuance of the performance-based restricted stock unit awards, Mr. Baum agreed to forfeit 1,050,000 RSUs subject to performance-based vesting granted to him in May 2013 and Mr. Boll agreed to forfeit the Boll Performance Equity Award granted to him in February 2015. As a result, the issuance of the performance-based RSUs awarded in April 2016 have been treated as modifications of the RSUs granted to Mr. Baum in May 2013 and Mr. Boll in February 2015 for accounting purposes. The Company used a lattice binomial model to estimate a derived service period of 33 months related to the performance-based vesting grants and used the following assumptions:

	2016
Market price	$	3.98
Contractual terms (in years)		5.00
Expected volatility		102	%
Risk-free interest rate		1.04	%
Dividend yield		-

During the year ended December 31, 2016, the Company granted an aggregate of 63,450 RSUs to its non-employee directors valued at $250. These RSUs vest in equal quarterly installments over a one-year period subject to the director’s continued service at the vesting date, but the issuance and delivery of these shares are deferred until the director resigns.

Grants During the Year Ended December 31, 2017

During the year ended December 31, 2017, the Company granted an aggregate of 62,892 RSUs to its non-employee directors valued at $200. These RSUs vest in equal quarterly installments over a one-year period subject to the director’s continued service at the vesting date, but the issuance and delivery of these shares are deferred until the director resigns.

A summary of the Company’s RSU activity and related information for the year ended December 31, 2017 is as follows:

	Number of RSUs			Weighted Average Grant Date Fair Value
RSUs unvested - January 1, 2017		1,292,876		$	2.43
RSUs granted		62,892			3.18
RSUs vested		(56,822	)	$	3.94
RSUs cancelled/forfeit		-
RSUs unvested at December 31, 2017		1,298,946		$	2.42

As of December 31, 2017, the total unrecognized compensation expense related to unvested RSUs was approximately $1,326 which is expected to be recognized over a weighted-average period of 0.9 years, based on estimated vesting schedules. The stock-based compensation for RSUs was $1,211 and $1,539 during the years ended December 31, 2017 and 2016, respectively.

The Company recorded stock-based compensation (including issuance of common stock for services and accrual for stock-based compensation) related to equity instruments granted to employees, directors and consultants as follows:

	For the		For the
	Year Ended		Year Ended
	December 31, 2017		December 31, 2016
Employees - selling and marketing	$	449	$	498
Employees - general and administrative		2,229		2,954
Directors - general and administrative		205		221
Consultants - selling and marketing		60		-
Other - general and administrative		-		115
Total	$	2,943	$	3,788

Warrants

From time to time, the Company issues warrants to purchase shares of the Company’s common stock to investors, lenders (see Note 11), underwriters and other non-employees for services rendered or to be rendered in the future.

A summary of warrant activity during the year ended December 31, 2017 is as follows:

	Number of Shares Subject to Warrants Outstanding			Weighted Avg. Exercise Price
Warrants outstanding - January 1, 2017		5,748,829		$	1.91
Granted		615,386			2.08
Exercised		(100,000	)		1.79
Expired		-
Warrants outstanding and exercisable - December 31, 2017		6,264,215		$	1.93
Weighted average remaining contractual life of the outstanding warrants in years - December 31, 2017		2.52

The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing warrants granted during the year ended December 31, 2016 related to settlement agreements:

	2016
Weighted-average fair value of warrants granted		2.88
Expected terms (in years)		5
Expected volatility		106	%
Risk-free interest rate		0.79	%
Dividend yield		-

	2017
Weighted-average fair value of warrants granted	$	1.70
Expected terms (in years)		7.00
Expected volatility		113.5	%
Risk-free interest rate		1.77	%
Dividend yield		-

All warrants outstanding as of December 31, 2017 are included in the following table:

	Warrants Outstanding					Warrants Exercisable
		Warrants		Exercise		Warrants		Expiration
Warrant Series	Issue Date	Outstanding		Price		Exercisable		Date
Lender warrants	5/11/2015		125,000	$	1.79		125,000	5/11/2025
Underwriter warrants	2/7/2013		55,688	$	5.25		55,688	2/7/2018
Settlement warrants	8/16/2016		40,000	$	3.75		40,000	8/16/2021
Warrants issued to investor relations consultant	7/19/2013		60,000	$	8.50		60,000	7/19/2018
Placement Agent Warrants	12/27/2016		210,313	$	1.79		210,313	12/27/2019
PIPE Investor Warrants	12/27/2016		5,157,828	$	1.79		5,157,828	12/27/2019
Lender warrants (see Note 11)	7/19/2017		615,386	$	2.08		615,386	7/19/2024
			6,264,215	$	1.93		6,264,215

Derivative Instruments

12 Months Ended

Dec. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments

NOTE 14. DERIVATIVE INSTRUMENTS

During the year ended December 31, 2016, the Company modified certain common stock purchase warrants issued in conjunction with debt which are detachable, or free standing, instruments. The warrants were considered a derivative liability upon modification and the estimated fair value of the warrants was reclassified from equity to liabilities. In addition, the Company recorded a derivative liability and debt discount associated with the estimated fair value of the embedded conversion feature in the Convertible Note (see Note 11). Both instruments contained a provision which allowed for one-time adjustments to their exercise or conversion prices. The one-time adjustment occurred upon the closing of the Company’s underwritten public offering of its common stock (see Note 13), on March 16, 2016, whereby the conversion and exercise prices were adjusted from $5.90 to $3.60 per share. At the time of the one-time adjustment, the Company reclassified the derivative liabilities to equity based on their then estimated fair value at that time. The Company estimated the fair value of the derivative liabilities utilizing Level 3 inputs. The Company used the Black-Scholes-Merton option pricing model as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, and risk-free rates) necessary to value these instruments.

The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing derivative liabilities:

	2016
Expected volatility	103 - 111	%
Risk-free interest rate	1.22 - 1.70	%
Dividend yield	-

The Company estimated the expected terms based on the remaining contractual life of the instruments on the date of the fair value measurement. The warrant expires on May 11, 2025 and the convertible note had an original maturity date of May 11, 2021.

The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs:

	December 31, 2016
Warrant derivative liability:
Balance at January 1, 2016	$	-
Modification of warrant and reclassification from equity to liabilities		675
Change in fair value		(211	)
Reclassification from liabilities to equity upon closing of public equity offering		(464	)
Balance at December 31, 2016	$	-

Embedded conversion feature derivative liability:
Balance at January 1, 2016	$	-
Embedded conversion feature in Convertible Note issued		2,322
Change in fair value		324
Reclassification from liabilities to equity upon closing of public equity offering		(2,646	)
Balance at December 31, 2016	$	-

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

NOTE 15. INCOME TAXES

The Company is subject to taxation in the United States, California, New Jersey, Texas and Pennsylvania. The provision for income taxes for the years ended December 31, 2017 and 2016 are summarized below:

	December 31, 2017			December 31, 2016
Current:
Federal	$	-		$	-
State		5			8
Total current	$	5		$	8

Deferred:
Federal	$	6,474		$	(5,623	)
State		(283	)		(1,713	)
Change in valuation allowance		(7,126	)		7,225
Total deferred		(935	)		(111	)
Income tax provision (benefit)	$	(930	)	$	(103	)

Income tax expense for the years ended December 31, 2017 and 2016, are recorded in the general and administrative expenses line item in the accompanying consolidated statements of operations.

A reconciliation of income taxes computed by applying the statutory U.S. income tax rate to the Company’s loss before income taxes to the income tax provision is as follows:

	December 31, 2017			December 31, 2016
U.S. federal statutory tax rate		35.00	%		35.00	%
Benefit of lower tax brackets		(1.00	)%		(1.00	)%
State tax benefit, net		1.60	%		0.08	%
Research and development credits		0.00	%		0.00	%
Employee stock based compensation		(0.84	)%		(1.47	)%
Loss on debt conversion		(2.39	)%		0.00	%
Capitalization of Subsidiary		0.00	%		0.00	%
Change in Rate		(62.97	)%		0.00	%
Other		3.04	%		(0.18	)%
Valuation allowance		34.82	%		(31.89	)%
Effective income tax rate		7.26	%		0.54	%

Deferred tax assets and liabilities reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows (in thousands):

	December 31, 2017			December 31, 2016
Deferred tax assets (liabilities):
NOL’s	$	17,405		$	21,555
Depreciation and amortization		58			199
Other		351			398
Research & development credits		596			556
Deferred stock compensation		2,534			3,875
Basis Difference in Eton		(985	)		-
Park stock purchase identifiable intangibles		(501	)		(936	)
Unrealized gain or loss on investments		-			-
Total deferred tax assets, net		19,458			25,647
Valuation allowance		(19,458	)		(26,583	)
Net deferred tax liabilities	$	-		$	(936	)

Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance decreased by approximately $7.1 and increased by approximately $7.2 during 2017 and 2016, respectively.

As of December 31, 2017, the Company had net operating loss carryforwards for federal income tax purposes of approximately $62,899 and federal research and development tax credits of approximately $354. Under new tax law, federal NOLs can be carried forward indefinitely for losses incurred after December 31, 2017. Losses incurred prior to the effective date are still subject to the 20 year carryforward. The federal research credits will expire beginning in the year 2026. As of December 31, 2017, the Company had net operating loss carryforwards for state income tax purposes of approximately $59,215 which expire beginning in the year 2017 and state research and development tax credits of approximately $305 which do not expire.

In March 2016, the FASB issued ASU 2016-09, Improvement to Employee Share – Based Payment Accounting. The new standard contains several amendments that will simplify the accounting for employee share-based payment transactions. The changes in the new standard eliminate the accounting for excess tax benefits to be recognized in additional paid-in capital and tax deficiencies recognized either in income tax provision or in additional paid-in capital. The Company’s deferred tax asset at December 31, 2017 did not include any excess tax benefits from employee stock option exercises, which are a component of the federal and state net operating loss carryforwards and on a go forward basis the excess tax benefits will be recognized as a component of income tax expense.

Utilization of the net operating losses may be subject to substantial annual limitation due to federal and state ownership change limitations provided by the Internal Revenue Code and similar state provisions. Such annual limitations could result in the expiration of the net operating losses ad credits before their utilization.

In June 2006, the FASB issued interpretation ASC 740-10-50, Accounting for Uncertainty in Income Tax. This pronouncement clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with ASC 740-10-50, Accounting for Income Taxes. This interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in the tax return. ASC 740 also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transaction. The Company adopted ASC 740-10-50 effective January 1, 2009. In accordance with ASC 740-10-50, the Company is classifying interest and penalties as a component of tax expense.

The Company did not have any unrecognized tax benefits as of December 31, 2017 and 2016, all of which is offset by a full valuation allowance. These unrecognized tax benefits, if recognized, would not affect the effective tax rate. There was no interest or penalties accrued at the adoption date and at December 31, 2016.

A reconciliation of the change in the UTB balance from January 1, 2017 to December 31, 2017 is as follows:

		Fed & State Tax
Balance at January 1, 2017	$	-
Additions for tax positions related to current year		-
Additions/(reductions) for tax positions related to prior years	$	-

Balance at December 31, 2017	$	-

Total unrecognized tax benefits as of December 31, 2017	$	-

On December 27, 2017, the United States Government passed new tax legislation that, among other provisions, will lower the corporate tax rate from 35% to 21%. In addition to applying the new lower corporate tax rate in 2018 and thereafter to any taxable income the Company may have, the legislation affects the way the Company can use and carryforward net operating losses previously accumulated and results in a revaluation of deferred tax assets and liabilities recorded on our consolidated balance sheet. Given the current deferred tax assets are offset by a full valuation allowance, these changes will have no net impact on the consolidated balance sheet. However, when the Company becomes profitable, it will receive a reduced benefit from such deferred tax assets. The effect of the legislation was a reduction in the deferred tax assets and the corresponding valuation allowance of approximately $8,059.

Employee Savings Plan

12 Months Ended

Dec. 31, 2017

Retirement Benefits [Abstract]

Employee Savings Plan

NOTE 16. EMPLOYEE SAVINGS PLAN

The Company has established an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code, effective January 1, 2014. The plan allows participating employees to deposit into tax deferred investment accounts up to 100% of their salary, subject to annual limits. The Company makes certain matching contributions to the plan in amounts up to 4% of the participants’ annual cash compensation, subject to annual limits. The Company contributed approximately $288 and $248 to the plan during the years ended December 31, 2017 and 2016, respectively.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

NOTE 17. COMMITMENTS AND CONTINGENCIES

Contingent Acquisition Obligation

On April 1, 2014, the Company acquired all of the outstanding membership interests of Pharmacy Creations, LLC (“PC”). The sellers of PC, were entitled to receive certain payments, including contingent consideration upon certain conditions. The estimated fair value of the contingent acquisition obligation was $483 and included in the contingent acquisition obligation in the accompanying balance sheet at December 31, 2015. During May 2016, the Company paid the sellers of PC $100 in cash and 75,000 shares of its common stock with a fair value of $302, as payment in full related to the contingent acquisition obligation. Related to the payment of the contingent acquisition obligation the Company recorded a gain of $81 during the year ended December 31, 2016, which is included in other income, net in the accompanying consolidated statement of operations.

Operating Leases

In May 2014, the Company entered into a lease agreement for 7,565 square feet of office space that commenced on September 1, 2014. In May 2017, the Company entered into an amended lease agreement, to lease an additional 2,635 square feet (10,200 square feet in total). Monthly rent following the amendment is $29, with a 3% increase in the base rent amount on an annual basis. The lease agreement allows for the monthly rent amount to be abated for two months at various times during the lease agreement and expires on December 31, 2021, and includes an option to extend the lease through December 31, 2027.

In January 2015, the Company entered into a commercial lease agreement, for the lease to Park of approximately 4,500 square feet of laboratory and office space. The monthly rent amount is $10 and includes annual increases of approximately 3%. The current lease term expires on December 31, 2020 and includes 2 options that allow for the lease term to be extended 10 additional years beyond the stated expiration date.

In February 2015, the Company entered into a lease agreement for approximately 8,600 square feet of laboratory, warehouse and office space in Ledgewood, New Jersey. The Company amended the lease agreement in July 2017, to add approximately 7,000 square feet of additional space. The lease term expires on July 31, 2022, and includes 2 options that allow for the lease term to be extended 10 additional years beyond the stated expiration date. The monthly rent amount is $15 and includes annual increases of approximately 3.75%, and the lease allowed for the first five months of rent amounts to be abated.

Rent expense for the years ended December 31, 2017 and 2016 was $649 and $668, respectively. The following represents future annual minimum lease payments, as of December 31, 2017:

2018	$	697
2019		697
2020		697
2021		571
2022		111
Total	$	2,773

Legal

Urigen, et. al, Litigation

On October 2014, the Company entered into a license agreement (the “Urigen License”) with Urigen Pharmaceuticals, Inc. (“Urigen”) for a license of certain U.S. patents and patent applications to develop and sell in the U.S. Urigen’s URG101 product, a heparin and alkalinized lidocaine compounded formulation for the prevention or treatment of disorders of the lower urinary tract. The Company, as the plaintiff, filed a civil action in the San Diego Superior Court against Urigen in December 2015, wherein the Company outlined serious concerns regarding material failures and inaccuracies of the representation and warranties provided by Urigen in the Urigen License, which have affected the Company’s ability to realize the expected benefit of the Urigen License. Urigen filed a cross-complaint in April 2016 for breach of contract asserting unpaid royalties totaling $698 and requesting a decree to cancel the Urigen Agreement. The Company filed another complaint in May 2016 with the U.S. District Court for the Southern District of California for declaratory judgment of the invalidity of the core patent filing related to Urigen’s URG 101. In June 2016, the Company received notice from Urigen of their election to terminate the Urigen License. In November 2016, the Company and Urigen entered into a settlement and mutual release agreement whereby all parties agreed to settle all disputes related to the Urigen License and associated litigation matters, the Company agreed to make a one-time payment to Urigen related to past sales of Urigen’s URG101 product and to cease selling the URG101 product over a certain period of time. During the year ended December 31, 2016, the Company recorded a gain related to the settlement with Urigen totaling $551 which is included in other income, net in the accompanying consolidated statement of operations.

Corwin, Kammer, et. al. Litigation

In February 2014, Robert Kammer (“Kammer”), the Company’s Chairman of the Board, filed a lawsuit in the San Diego Superior Court against Merlyn Corwin (“Corwin”) to enforce his contract rights related to a settlement agreement the parties had previously entered into involving shares of the Company’s common stock. Corwin filed an answer to the complaint in March 2014 and in June 2014 filed the first amended cross complaint adding the Company as a cross-defendant. In August 2014, Corwin filed a seconded amended cross complaint (the “SACC”) which added Mark Baum (“Baum”), the Company’s Chief Executive Officer, and an individual who previously provided consulting services to the Company as additional cross-defendants. The SACC alleged numerous causes of action including securities fraud, concealment, misrepresentations, inducement of misrepresentations, rescission – undue influence, intentional infliction of emotional distress and declaratory relief of invalidity of the settlement agreement. In September 2014, the Company and Baum filed an anti-strategic lawsuit against public participation motion (“Anti-SLAPP”), arguing all allegations in the SACC were based on protected activity under the litigation privilege. Kammer also filed an Anti-SLAPP motion in October 2014. In November 2014, the Company, Baum and Kammer were granted both Anti-SLAPP motions, with the ruling judge deciding that the parties successfully demonstrated that the allegations arose from activity protected by the litigation privilege. The judge further found that the evidence Corwin relied upon in her arguments failed to demonstrate a probability that she could prevail on any of the claims. The court then ordered Corwin to pay the Company’s and Baum’s attorney fees and the case was dismissed. In May 2015, Corwin filed an appeal and in November 2015, the appellate court reversed the Anti-SLAPP decision of the trial court. In April 2016, the Company and Baum filed a demurrer to the SACC. The court ordered a ruling on the demurrer in June 2016, dismissing most of the causes of action against Baum and the Company, but leaving the claim for fraud by concealment and intentional infliction of emotional distress. In August 2016, all parties related to this litigation entered into a settlement and mutual release agreement, whereby all parties agreed to settle all disputes and release one another of any legal claims. The Company issued 40,000 at-the-money warrants (see Note 13) as part of the settlement consideration. The estimated fair value of the warrant (see Note 13) and associated legal expenses were recorded in general and administrative expenses during the year ended December 31, 2016 in the accompanying consolidated statement of operations.

Dr. Sobol Litigation

In December 2016, Louis L. Sobol, M.D. (“Sobol”) filed a lawsuit in the U.S. District Court for the Eastern District of Michigan, Southern Division against the Company, asserting claims on behalf of himself and an as-yet-uncertified class of consumers. The claims allege violations under the Telephone Consumer Protection Act, 47 U.S.C. § 227 via the Company’s alleged transmittal of advertisements to its clients via facsimile. The case is currently in the discovery phase, and the Company expects Dr. Sobol to likely request the court to certify the class at some point, possibly during 2018. The Company believes the claims are frivolous and have previously and will continue to dispute all claims against it and intends to vigorously defend these allegations.

Allergan USA Litigation

In September 2017, Allergan USA, Inc. (“Allergan”) filed a lawsuit in the U.S. District Court for the Central District of California against the Company, primarily claiming violations under the federal Lanham Act and other state laws. In December, the Company filed counterclaims against Allergan alleging similar violations under the federal Lanham Act and other state laws and the case is currently in the beginning stages of discovery, with a trial date set for April 2019. The Company has previously and continues to dispute all claims against it and intends to vigorously defend these allegations.

Spectrum Litigation

In February 2018, the Company filed a complaint against Spectrum Laboratory Products, Inc., Spectrum Chemical Manufacturing Corp. and Spectrum Pharmacy Products, Inc. (collectively “Spectrum”) in the Los Angeles County Superior Court asserting claims for breach of contract, breach of implied covenant of good faith and fair dealing, violation of California Commercial Code Section 2101 and fraud. The claims stem from prior business dealings between the Company and Spectrum and allege false representation by Spectrum regarding their products, fraudulent labeling and misrepresentations of approved product usages. The complaint has been filed with the Court and to date, Spectrum has provided the Company no response nor filed any answer with the Court. We intend to fully purse any and all legal remedies available to us against Spectrum.

General and Other

In the ordinary course of business, the Company may face various claims brought by third parties and the Company may, from time to time, make claims or take legal actions to assert the Company’s rights, including intellectual property disputes, employment, contractual disputes and other commercial disputes. Any of these claims could subject the Company to litigation. Management believes the outcomes of currently pending claims are not likely to have a material effect on the Company’s consolidated financial position and results of operations.

During the year ended December 31, 2017, the Company estimated and accrued costs totaling $450 related to expected settlement costs for litigation matters, which is recorded in accounts payable and accrued expenses in the consolidated balance sheets.

Indemnities

In addition to the indemnification provisions contained in the Company’s charter documents, the Company generally enters into separate indemnification agreements with each of the Company’s directors and officers. These agreements require the Company, among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys’ fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual’s status or service as the Company’s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification by the Company. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying consolidated balance sheets.

Insurance Claims

In June 2016, the Company’s Texas based facility was damaged related to a malfunction with the property’s sprinkler system. The Company commenced restoration efforts and filed claims for damages under its insurance policies, including claims related to business interruption. During the year ended December 31, 2016, the Company recorded the insurance claim of $861 in other income, net in the accompanying consolidated statement of operations which reflected amounts paid by its insurance carrier related to the claims filed for property damage and business interruption.

Klarity License Agreement – Related Party

In April 2017, the Company entered into a license agreement (the “Klarity License Agreement”) with Richard L. Lindstrom, M.D., a member of its Board of Directors. Pursuant to the terms of the Klarity License Agreement, the Company licensed certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license the topical ophthalmic solution Klarity used to protect and rehabilitate the ocular surface (the “Klarity Product”).

Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% to 6% of net sales, dependent upon the final formulation of the Klarity Product sold. In addition, the Company is required to make certain milestone payments to Dr. Lindstrom including: (i) an initial payment of $50 upon execution of the Klarity License Agreement, (ii) a second payment of $50 following the first $50 in net sales of the Klarity Product; and (iii) a final payment of $50 following the first $100 in net sales of the Klarity Product. All of the above referenced milestone payments are payable at the Company’s election in cash or shares of the Company’s restricted common stock. Dr. Lindstrom was paid $50 in cash during the year ended December 31, 2017, and was due an additional $19 at December 31, 2017. Dr. Lindstrom is a member of the Company’s Board of Directors, chairman of its Compensation Committee and a member of its Nomination and Corporate Governance Committee.

Sales and Marketing Agreements

During 2017, the Company entered various sales and marketing agreements with certain organizations, to provide exclusive sales and marketing representation services to Imprimis in select geographies in the U.S., in connection with our ophthalmic compounded formulations.

Under the terms of the sales and marketing agreements, the Company is required to make commission payments to equal to 10% - 14% of net sales for products above and beyond the initial existing sales amounts. In addition, the Company is required to make periodic milestone payments to certain organizations in shares of the Company’s restricted common stock if net sales in the assigned territory reach certain future levels by the end of their terms, as applicable. No stock based payments were made and $183 were incurred under these agreements for commission expenses during the year ended December 31, 2017.

Asset Purchase, License and Related Agreements

The Company has acquired and sourced intellectual property rights related to certain proprietary innovations from certain inventors and related parties (the “Inventors”) through multiple asset purchase agreements, license agreements, strategic agreements and commission agreements. In general, these agreements provide that the Inventors will cooperate with the Company in obtaining patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts to research, develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired a right of first refusal on additional intellectual property and drug development opportunities presented by these Inventors.

In consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the first investigational new drug application (“IND”) with the FDA for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company’s development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to the Inventors. $108 and $3 were accrued in accounts payable and accrued expenses under these agreements for royalty expenses incurred during the years ended December 31, 2017 and 2016, respectively.

Segment Information and Concentrations

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Segment Information and Concentrations

NOTE 18. SEGMENT INFORMATION AND CONCENTRATIONS

The Company operates the business on the basis of a single reportable segment, which is the business of developing proprietary drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services and drug development. While the Company is described as having certain individual businesses, in general, those business operations often overlap, decisions and resources may be intermingled between components and discrete financial information about the businesses, on an individual basis, is not available. The Company’s chief operating decision-maker is the Chief Executive Officer, who evaluates the Company as a single operating segment.

The Company categorizes revenues by geographic area based on selling location. All operations are currently located in the United States; therefore, total revenues for 2017 and 2016 are attributed to the United States. All long-lived assets at December 31, 2017 and 2016 are located in the United States.

The Company sells its compounded formulations to a large number of customers. No single customer contributed 10% or more of the Company’s total pharmacy sales in the years ended December 31, 2017 and 2016.

The Company receives its active pharmaceutical ingredients from three main suppliers during the years ended December 31, 2017 and 2016. These suppliers collectively accounted for 68% and 69% of drug and chemical purchases during the years ended December 31, 2017 and 2016, respectively.

Subsequent Events

12 Months Ended

Dec. 31, 2017

Subsequent Events [Abstract]

Subsequent Events

NOTE 19. SUBSEQUENT EVENTS

The Company has performed an evaluation of events occurring subsequent to December 31, 2017 through the filing date of this Annual Report on Form 10-K (the “Annual Report”). Based on its evaluation, nothing other than the events described below needs to be disclosed.

In January 2018, the Company sold 33,800 shares of common stock under the Sales Agreement and received net proceeds of $57, after deducting offering related expenses and commissions.

In January 2018, the Company issued 25,273 shares of its restricted common stock, with a fair value of $44, in lieu of a cash payment for royalty expenses.

Restricted stock units granted in February 2015 to Andrew R. Boll, the Company’s Chief Financial Officer, vested, and in February 2018, 30,000 shares the Company’s common stock were issued to Mr. Boll.

Restricted stock units granted in February 2015 to John P. Saharek, the Company’s Chief Commercial Officer, vested, and in February 2018, 30,000 shares the Company’s common stock were issued to Mr. Saharek.

In March 2018, the Company issued 35,427 shares of its restricted common stock, with a fair value of $64, in lieu of a cash payment for royalty expenses.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Use of Estimates

Use of Estimates

Liquidity

Liquidity

Revenue Recognition and Deferred Revenue

Revenue Recognition and Deferred Revenue

Product Revenues

License Revenues

Cost of Sales

Cost of Sales

Research and Development

Research and Development

Debt Issuance Costs and Debt Discount

Debt Issuance Costs and Debt Discount

Intellectual Property

Intellectual Property

Income Taxes

Income Taxes

Cash and Cash Equivalents

Cash and Cash Equivalents

Cash equivalents include short-term, highly liquid investments with maturities of three months or less at the time of acquisition.

Concentrations of Credit Risk

Concentrations of Credit Risk

Accounts Receivable

Accounts Receivable

Inventories

Inventories

Investment in Eton Pharmaceuticals, Inc.

Investment in Eton Pharmaceuticals, Inc.

Property, Plant and Equipment

Property, Plant and Equipment

Business Combinations

Business Combinations

	●	future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and

	●	discount rates utilized in valuation estimates.

Goodwill and Intangible Assets

Goodwill and Intangible Assets

	●	significant underperformance of the Company’s business relative to expected operating results;

	●	significant adverse economic and industry trends;

	●	significant decline in the Company’s market capitalization for an extended period of time relative to net book value; and

	●	expectations that a reporting unit will be sold or otherwise disposed.

The goodwill impairment test consists of a two-step process as follows:

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Third Party Billing and Collection Agreements

Third Party Billing and Collection Agreements

Deferred Rent

Deferred Rent

Fair Value Measurements

Fair Value Measurements

●	Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.
●	Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
●	Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.

Derivative Instruments

Derivative Instruments

Stock-Based Compensation

Stock-Based Compensation

Basic and Diluted Net Loss per Common Share

Basic and Diluted Net Loss per Common Share

The following table shows the computation of basic and diluted net loss per share of common stock for the years ended December 31, 2017 and 2016:

	For the Year Ended December 31, 2017			For the Year Ended December 30, 2016

Numerator – net loss	$	(11,985	)	$	(19,087	)
Denominator – weighted average
number of shares outstanding, basic and diluted		20,027,712			12,743,184
Net loss per share, basic and diluted	$	(0.60	)	$	(1.50	)

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Schedule of Basic Earnings Per Common Share

The following table shows the computation of basic and diluted net loss per share of common stock for the years ended December 31, 2017 and 2016:

	For the Year Ended December 31, 2017			For the Year Ended December 30, 2016

Numerator – net loss	$	(11,985	)	$	(19,087	)
Denominator – weighted average
number of shares outstanding, basic and diluted		20,027,712			12,743,184
Net loss per share, basic and diluted	$	(0.60	)	$	(1.50	)

Investment in Eton Pharmaceuticals, Inc. and Agreements - Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2017

Schedule of Condensed Income Statement

The unaudited condensed results of operations information of Eton is summarized below (in thousands):

	From the period beginning April 27, 2017 (inception) to December 31, 2017
Revenues, net	$	-
Loss from operations		8,036
Net loss	$	(8,036	)

Schedule of Condensed Balance Sheet

The unaudited condensed balance sheet information of Eton is summarized below (in thousands):

	At December 31, 2017
Current assets	$	13,440
Total assets		13,440

Current liabilities		764
Stockholders’ equity		12,676
Total liabilities and stockholders’ equity	$	13,440

Inventories (Tables)

12 Months Ended

Dec. 31, 2017

Inventory Disclosure [Abstract]

Schedule of Inventories

The composition of inventories as of December 31, 2017 and 2016 was as follows:

	December 31, 2017		December 31, 2016

Raw materials	$	956	$	669
Finished goods		1,293		1,172
Total inventories	$	2,249	$	1,841

Prepaid Expenses and Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2017

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:

	December 31, 2017		December 31, 2016
Prepaid insurance	$	164	$	315
Other prepaid expenses		426		517
Deposits and other current assets		124		106
Total prepaid expenses and other current assets	$	714	$	938

Asset Sales and Note Receivable (Tables)

12 Months Ended

Dec. 31, 2017

Asset Sales And Note Receivable

Schedule of Future Minimum Payments to Note Receivable

At December 31, 2017, future minimum payments to the Company under its note receivable were as follows:

	Amount
2018	$	135
2019		116
2020		116
2021		77
Total minimum note receivable, including interest		444
Less: amount representing interest income		47
Present value of future minimum note receivable		397
Less: current portion		95
Note receivable net of current portion	$	302

Schedule of Assets and Note Receivable

Assets sold during the year ended December 31, 2017 consisted of the following:

	December 31, 2017
Inventories	$	413
Furniture and equipment		226
		639
Loss on asset sale		(127	)
Assets sold	$	512

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Property, plant and equipment at December 31, 2017 and 2016 consisted of the following:

	December 31, 2017			December 31, 2016
Property, plant and equipment, net;
Computer software and hardware	$	1,239		$	831
Furniture and equipment		377			424
Lab and pharmacy equipment		2,545			2,559
Leasehold improvements		4,810			4,836
		8,971			8,650
Accumulated depreciation and amortization		(2,756	)		(1,355	)
	$	6,215		$	7,295

Intangible Assets and Goodwill (Tables)

12 Months Ended

Dec. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

The Company’s intangible assets at December 31, 2017 consisted of the following:

	Amortization
	periods			Accumulated						Net
	(in years)	Cost		amortization			Impairment			Carrying value
Patents	17-19 years	$	365	$	(21	)	$	-		$	344
Licenses	20 years		50		-			-			50
Trademarks	Indefinite		276		-			-			276
Customer relationships	3-15 years		2,998		(813	)		(15	)		2,170
Trade name	5 years		16		(9	)		(1	)		6
Non-competition clause	3-4 years		294		(273	)		(20	)		1
State pharmacy licenses	25 years		45		(4	)		(28	)		13
		$	4,044	$	(1,120	)	$	(64	)	$	2,860

Schedule of Amortization Expenses for Intangible Assets

Amortization expense for intangible assets for the year ended December 31 was as follows:

	For the		For the
	Year Ended		Year Ended
	December 31, 2017		December 31, 2016
Patents	$	15	$	5
Customer relationships		257		255
Trade name		3		3
Non-competition clause		87		86
State pharmacy licenses		2		2
	$	364	$	351

Schedule of Estimated Future Amortization Expense

Estimated future amortization expense for the Company’s intangible assets at December 31, 2017 is as follows:

Years ending December 31,
2018	$	228
2019		225
2020		222
2021		222
2022		222
Thereafter		1,741
	$	2,860

Schedule of Goodwill

The changes in the carrying value of the Company’s goodwill during the years ended December 31, 2017 and 2016 were as follows:

Balance at January 1, 2016	$	2,466
Impairment of ImprimisRx TX		(239	)
Balance at December 31, 2016	$	2,227
No changes		-
Balance at December 31, 2017	$	2,227

Accounts Payable and Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2017

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses at December 31, 2017 and 2016 consisted of the following:

	December 31, 2017			December 31, 2016
Accounts payable	$	3,241		$	2,999
Deferred rent		388			412
Accrued interest (see Note 11)		256			116
Accrued exit fee for notes payable (see Note 11)		800			667
Building lease liability		-			11
Total accounts payable and accrued expenses		4,685			4,205
Less: Current portion		(3,885	)		(3,538	)
Non-current total accrued expenses	$	800		$	667

Debt (Tables)

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Summary of Notes Payable

Notes payable at December 31, 2017 were as follows:

	December 31, 2017
SWK note	$	16,000
Less: Discount on note		(1,992	)
Less: Current portion		-
Long-term portion	$	14,008

Summary of Future Minimum Payments

Future minimum payments under notes payable outstanding at December 31, 2017 are as follows:

Year Ending December 31,	Amount
2018	$	1,947
2019		3,657
2020		3,440
2021		3,214
2022		11,201
Total minimum payments		23,459
Less: amount representing interest		(7,459	)
Notes payable, gross	$	16,000

Capital Lease Obligation (Tables)

12 Months Ended

Dec. 31, 2017

Leases [Abstract]

Schedule of Future Payment Under Capital Lease

At December 31, 2017, future payments under the Company’s capital lease were as follows:

	Amount
2018	$	773
2019		751
Total minimum lease payments		1,524
Less: amount representing interest payments		(96	)
Present value of future minimum lease payment		1,427
Less: unamortized discount		(110	)
		1,317
Less: current portion, net of unamortized discount		(598	)
Capital lease obligation net of current portion and unamortized discount	$	720

Stockholders' Equity and Stock-based Compensation (Tables)

12 Months Ended

Dec. 31, 2017

Schedule of Stock Option Plan Activity

A summary of stock option activity under the Plan for the year ended December 31, 2017 is as follows:

	Number of shares			Weighted Avg. Exercise Price		Weighted Avg. Remaining Contractual Life		Aggregate Intrinsic Value
Options outstanding - January 1, 2017		2,013,313		$	6.20
Options granted		538,000		$	2.37
Options exercised		-		$	-
Options cancelled/forfeit		(291,334	)	$	4.45
Options outstanding - December 31, 2017		2,259,979		$	5.51		6.11	$	1
Options exercisable		989,664		$	5.74		6.38	$	-
Options vested and expected to vest		2,137,854		$	5.51		6.12	$	1

Schedule of Fair Value Assumption

The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees:

	2017			2016
Weighted-average fair value of options granted	$	2.04		$	3.91
Expected terms (in years)		5.81 - 6.11			5.81 - 6.11
Expected volatility		112 - 117	%		101 - 112	%
Risk-free interest rate		1.77 - 2.01	%		1.07 - 1.70	%
Dividend yield		-			-

The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to consultants:

	2016
Weighted-average fair value of options granted	$	6.18
Expected terms (in years)		10
Expected volatility		109	%
Risk-free interest rate		1.06	%
Dividend yield		-

Schedule of Shares Outstanding and Exercisable

The following table summarizes information about stock options outstanding and exercisable at December 31, 2017:

	Options Outstanding						Options Exercisable
			Weighted
			Average		Weighted				Weighted
			Remaining		Average				Average
	Number		Contractual		Exercise		Number		Exercise
Range of Exercise Prices	Outstanding		Life in Years		Price		Exercisable		Price
$1.47 - $2.60		584,500		8.15	$	2.18		197,997	$	2.35
$3.20 - $4.50		539,906		7.94	$	3.97		286,855	$	3.99
$5.49 - $6.36		106,536		5.61	$	5.95		103,092	$	5.97
$6.64 - $8.99		1,024,007		4.05	$	7.98		396,690	$	8.18
$42.80		5,030		2.62	$	42.80		5,030	$	42.80
$1.47 - $42.80		2,259,979		6.11	$	5.51		989,664	$	5.74

Schedule of Market-based Vesting Conditions for Restricted Stock Units Granted

These market-based accelerated vesting conditions and share amounts (in aggregate) are set forth below:

Tranche	Number of shares	Target share price
Tranche 1	230,000 shares	$9.00 or greater
Tranche 2	230,000 shares	$10.00 or greater
Tranche 3	230,000 shares	$12.00 or greater
Tranche 4	230,000 shares	$14.00 or greater
Tranche 5	287,500 shares	$15.00 or greater

Schedule of Assumptions Used

The Company used a lattice binomial model to estimate a derived service period of 33 months related to the performance-based vesting grants and used the following assumptions:

	2016
Market price	$	3.98
Contractual terms (in years)		5.00
Expected volatility		102	%
Risk-free interest rate		1.04	%
Dividend yield		-

Schedule of Restricted Stock Units Activity

A summary of the Company’s RSU activity and related information for the year ended December 31, 2017 is as follows:

	Number of RSUs			Weighted Average Grant Date Fair Value
RSUs unvested - January 1, 2017		1,292,876		$	2.43
RSUs granted		62,892			3.18
RSUs vested		(56,822	)	$	3.94
RSUs cancelled/forfeit		-
RSUs unvested at December 31, 2017		1,298,946		$	2.42

Schedule of Stock Based Compensation Granted to Employees Directors Consultants

	For the		For the
	Year Ended		Year Ended
	December 31, 2017		December 31, 2016
Employees - selling and marketing	$	449	$	498
Employees - general and administrative		2,229		2,954
Directors - general and administrative		205		221
Consultants - selling and marketing		60		-
Other - general and administrative		-		115
Total	$	2,943	$	3,788

Schedule of Warrants Activity

A summary of warrant activity during the year ended December 31, 2017 is as follows:

	Number of Shares Subject to Warrants Outstanding			Weighted Avg. Exercise Price
Warrants outstanding - January 1, 2017		5,748,829		$	1.91
Granted		615,386			2.08
Exercised		(100,000	)		1.79
Expired		-
Warrants outstanding and exercisable - December 31, 2017		6,264,215		$	1.93
Weighted average remaining contractual life of the outstanding warrants in years - December 31, 2017		2.52

Schedule of Warrants Outstanding and Warrants Exercisable

All warrants outstanding as of December 31, 2017 are included in the following table:

	Warrants Outstanding					Warrants Exercisable
		Warrants		Exercise		Warrants		Expiration
Warrant Series	Issue Date	Outstanding		Price		Exercisable		Date
Lender warrants	5/11/2015		125,000	$	1.79		125,000	5/11/2025
Underwriter warrants	2/7/2013		55,688	$	5.25		55,688	2/7/2018
Settlement warrants	8/16/2016		40,000	$	3.75		40,000	8/16/2021
Warrants issued to investor relations consultant	7/19/2013		60,000	$	8.50		60,000	7/19/2018
Placement Agent Warrants	12/27/2016		210,313	$	1.79		210,313	12/27/2019
PIPE Investor Warrants	12/27/2016		5,157,828	$	1.79		5,157,828	12/27/2019
Lender warrants (see Note 11)	7/19/2017		615,386	$	2.08		615,386	7/19/2024
			6,264,215	$	1.93		6,264,215

Warrants [Member]

Schedule of Fair Value Assumption

	2016
Weighted-average fair value of warrants granted		2.88
Expected terms (in years)		5
Expected volatility		106	%
Risk-free interest rate		0.79	%
Dividend yield		-

	2017
Weighted-average fair value of warrants granted	$	1.70
Expected terms (in years)		7.00
Expected volatility		113.5	%
Risk-free interest rate		1.77	%
Dividend yield		-

Derivative Instruments (Tables)

12 Months Ended

Dec. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Liabilities at Fair Value

The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing derivative liabilities:

	2016
Expected volatility	103 - 111	%
Risk-free interest rate	1.22 - 1.70	%
Dividend yield	-

Fair Value at Reconciliation of Measured Liabilities

The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs:

	December 31, 2016
Warrant derivative liability:
Balance at January 1, 2016	$	-
Modification of warrant and reclassification from equity to liabilities		675
Change in fair value		(211	)
Reclassification from liabilities to equity upon closing of public equity offering		(464	)
Balance at December 31, 2016	$	-

Embedded conversion feature derivative liability:
Balance at January 1, 2016	$	-
Embedded conversion feature in Convertible Note issued		2,322
Change in fair value		324
Reclassification from liabilities to equity upon closing of public equity offering		(2,646	)
Balance at December 31, 2016	$	-

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule of Provision for Income Taxes

The provision for income taxes for the years ended December 31, 2017 and 2016 are summarized below:

	December 31, 2017			December 31, 2016
Current:
Federal	$	-		$	-
State		5			8
Total current	$	5		$	8

Deferred:
Federal	$	6,474		$	(5,623	)
State		(283	)		(1,713	)
Change in valuation allowance		(7,126	)		7,225
Total deferred		(935	)		(111	)
Income tax provision (benefit)	$	(930	)	$	(103	)

Schedule of Income Tax Reconciliation

A reconciliation of income taxes computed by applying the statutory U.S. income tax rate to the Company’s loss before income taxes to the income tax provision is as follows:

	December 31, 2017			December 31, 2016
U.S. federal statutory tax rate		35.00	%		35.00	%
Benefit of lower tax brackets		(1.00	)%		(1.00	)%
State tax benefit, net		1.60	%		0.08	%
Research and development credits		0.00	%		0.00	%
Employee stock based compensation		(0.84	)%		(1.47	)%
Loss on debt conversion		(2.39	)%		0.00	%
Capitalization of Subsidiary		0.00	%		0.00	%
Change in Rate		(62.97	)%		0.00	%
Other		3.04	%		(0.18	)%
Valuation allowance		34.82	%		(31.89	)%
Effective income tax rate		7.26	%		0.54	%

Schedule of Deferred Tax Assets and Liabilities

Significant components of the Company’s deferred tax assets are as follows (in thousands):

	December 31, 2017			December 31, 2016
Deferred tax assets (liabilities):
NOL’s	$	17,405		$	21,555
Depreciation and amortization		58			199
Other		351			398
Research & development credits		596			556
Deferred stock compensation		2,534			3,875
Basis Difference in Eton		(985	)		-
Park stock purchase identifiable intangibles		(501	)		(936	)
Unrealized gain or loss on investments		-			-
Total deferred tax assets, net		19,458			25,647
Valuation allowance		(19,458	)		(26,583	)
Net deferred tax liabilities	$	-		$	(936	)

Schedule of Change in Unrecognized Tax Benefits

A reconciliation of the change in the UTB balance from January 1, 2017 to December 31, 2017 is as follows:

		Fed & State Tax
Balance at January 1, 2017	$	-
Additions for tax positions related to current year		-
Additions/(reductions) for tax positions related to prior years	$	-

Balance at December 31, 2017	$	-

Total unrecognized tax benefits as of December 31, 2017	$	-

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Payments Under Leases

The following represents future annual minimum lease payments, as of December 31, 2017:

2018	$	697
2019		697
2020		697
2021		571
2022		111
Total	$	2,773

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	8 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Net loss		$ 11,985	$ 19,087
Accumulated deficit	$ 88,836	88,836	76,851
Net cash used in operating activities		8,803	11,215
Cash resources and restricted investments	4,219	4,219
Deposit coverage limits by FDIC, per owner		250
Cash deposits in excess of FDIC limits	3,969	3,969
Accounts receivable, net of allowance for doubtful accounts	275	275	422
Gain on deconsolidation of Eton Pharmaceuticals		5,725
Equity in loss of Eton Pharmaceuticals		2,218
Investment in Eton Pharmaceuticals, Inc.	3,507	$ 3,507
Property plant and equipment useful life		3 years	5 years
Impairment of long-lived assets			$ 303
Restricted cash	200	$ 200	$ 200
January 1, 2018 [Member]
Right of use assets	2,400	2,400
Operating lease, liability	3,000	$ 3,000
Restricted Stock Units [Member]
Number of shares vested during the period		137,067	80,245
Deferred Acquisition Obligations, Convertible Note Payable, Stock Options, Unvested RSUs and Warrants [Member]
Antidilutive securities		9,980,454	9,162,259
Billing and Collection Agreement [Member] \| Third Party [Member]
Percentage of billing and collection amount		55.00%
Billing and collection management expense		$ 0	$ 55
Due to related party	41	$ 41	73
Intangible Assets [Member]
Impairment of long-lived assets			64
Goodwill [Member]
Impairment of long-lived assets			$ 239
Patents [Member]
Patent estimated useful life		20 years
Eton Pharmaceuticals, Inc. [Member]
Net loss	$ 8,036
Proceeds from wholly owned subsidiary		$ 18
Number of common stock shares owned		3,500,000
Equity interest percentage	27.00%	27.00%

Summary of Significant Accounting Policies - Schedule of Basic Earnings Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Numerator - net loss	$ (11,985)	$ (19,087)
Denominator - weighted average number of shares outstanding, basic and diluted	20,027,712	12,743,184
Net income (loss) per share, basic and diluted	$ 0.60	$ (1.50)

Investment in Eton Pharmaceuticals, Inc. and Agreements - Related Party Transactions (Details Narrative) - Eton Pharmaceuticals, Inc. [Member] - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
	May 02, 2017	May 31, 2017	Dec. 31, 2017	Apr. 29, 2017
Due from related parties			$ 50
Ownership percentage			27.00%
Eton License Agreements [Member]
Royalty payment percentage on net sales		6.00%
Royalty payment percentage on net sales patent claims not issued		3.00%
Payment on issuances of patent		$ 50
Proceeds from sale of equity securities			$ 10,000
Management Services Agreement [Member]
Monthly payment	$ 10
Amount paid for services				$ 40

Investment in Eton Pharmaceuticals, Inc. and Agreements - Related Party Transactions - Schedule of Condensed Income Statement (Details) - USD ($) $ in Thousands	8 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Loss from operations		$ (12,163)	$ (15,882)
Net loss		$ (11,985)	$ (19,087)
Eton Pharmaceuticals, Inc. [Member]
Revenues, net
Loss from operations	8,036
Net loss	$ (8,036)

Investment in Eton Pharmaceuticals, Inc. and Agreements - Related Party Transactions - Schedule of Condensed Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current assets	$ 8,806	$ 14,753
Total assets	23,917	27,247
Current liabilities	5,774	9,905
Stockholders' equity	2,615	6,432	$ (1,385)
Total liabilities and stockholders' equity	23,917	$ 27,247
Eton Pharmaceuticals, Inc. [Member]
Current assets	13,440
Total assets	13,440
Current liabilities	764
Stockholders' equity	12,676
Total liabilities and stockholders' equity	$ 13,440

Restricted Cash (Details Narrative) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Cash and Cash Equivalents [Abstract]
Money market account	$ 200	$ 200

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 956	$ 669
Finished goods	1,293	1,172
Total inventories	$ 2,249	$ 1,841

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid insurance	$ 164	$ 315
Other prepaid expenses	426	517
Deposits and other current assets	124	106
Total prepaid expenses and other current assets	$ 714	$ 938

Asset Sales and Note Receivable (Details Narrative) - USD ($) $ in Thousands		1 Months Ended		12 Months Ended
	Jun. 27, 2017	Jun. 30, 2017	Feb. 28, 2017	Dec. 31, 2017	Dec. 31, 2016
Loss on sale of assets				$ 354
Pharmacy Solutions Central, LLC [Member]
Payment to closing cash amount	$ 410
Debt interest rate	6.00%
Debt monthly payment	$ 10
Debt annual principal payment	462
Pharmacy Solutions Central, LLC [Member] \| December 31, 2017 [Member]
Debt monthly payment	365
Imprimis TX [Member]
Loss on sale of assets				173
Asset Purchase Agreement [Member]
Note due amount				400
Loss on sale of assets				69
Loss from sale of equipment		$ 60
Loss on equipment				$ 52
Asset Purchase Agreement [Member] \| Pharmacy Solutions Central, LLC [Member]
Total purchase price	450
Payment to closing cash amount	$ 40
Stock Purchase Agreement [Member] \| Livernois [Member]
Sale of stock percentage			100.00%
Payment of consideration amount			$ 10
Lease obligation			$ 113

Asset Sales and Note Receivable - Schedule of Future Minimum Payments to Note Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Asset Sales And Note Receivable
2018	$ 135
2019	116
2020	116
2021	77
Total minimum payments note receivable, including interest	444
Less: amount representing interest income	47
Present value of future minimum note receivable	397
Less: current portion	95
Note receivable net of current portion	$ 302

Asset Sales and Note Receivable - Schedule of Assets Note Receivable (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Asset Sales And Note Receivable
Inventories	$ 413
Furniture and equipment	226
Asset held for sale	639
Loss on asset sale	(127)
Assets sold	$ 512

Property, Plant and Equipment (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation and amortization of property, plant and equipment	$ 1,401	$ 1,055

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Computer software and hardware	$ 1,239	$ 831
Furniture and equipment	377	424
Lab and pharmacy equipment	2,545	2,559
Leasehold improvements	4,810	4,836
Furniture and equipment, gross	8,971	8,650
Accumulated depreciation and amortization	(2,756)	(1,355)
Furniture and equipment, Net	$ 6,215	$ 7,295

Intangible Assets and Goodwill - Schedule of Intangible Assets (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($)
Cost	$ 4,044
Accumulated amortization	(1,120)
Impairment	(64)
Net Carrying value	$ 2,860
Patents [Member]
Amortization periods (in years)	20 years
Cost	$ 365
Accumulated amortization	(21)
Impairment
Net Carrying value	$ 344
Patents [Member] \| Minimum [Member]
Amortization periods (in years)	17 years
Patents [Member] \| Maximum [Member]
Amortization periods (in years)	19 years
Licenses [Member]
Amortization periods (in years)	20 years
Cost	$ 50
Accumulated amortization
Impairment
Net Carrying value	$ 50
Trademarks [Member]
Amortization periods description	Indefinite
Cost	$ 276
Accumulated amortization
Impairment
Net Carrying value	276
Customer Relationships [Member]
Cost	2,998
Accumulated amortization	(813)
Impairment	(15)
Net Carrying value	$ 2,170
Customer Relationships [Member] \| Minimum [Member]
Amortization periods (in years)	3 years
Customer Relationships [Member] \| Maximum [Member]
Amortization periods (in years)	15 years
Trade Name [Member]
Amortization periods (in years)	5 years
Cost	$ 16
Accumulated amortization	(9)
Impairment	(1)
Net Carrying value	6
Non-Competition Clause [Member]
Cost	294
Accumulated amortization	(273)
Impairment	(20)
Net Carrying value	$ 1
Non-Competition Clause [Member] \| Minimum [Member]
Amortization periods (in years)	3 years
Non-Competition Clause [Member] \| Maximum [Member]
Amortization periods (in years)	4 years
State Pharmacy Licenses [Member]
Amortization periods (in years)	25 years
Cost	$ 45
Accumulated amortization	(4)
Impairment	(28)
Net Carrying value	$ 13

Intangible Assets and Goodwill - Schedule of Amortization Expenses for Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Amortization of intangible assets	$ 364	$ 351
Patents [Member]
Amortization of intangible assets	15	5
Customer Relationships [Member]
Amortization of intangible assets	257	255
Trade Name [Member]
Amortization of intangible assets	3	3
Non-Competition Clause [Member]
Amortization of intangible assets	87	86
State Pharmacy Licenses [Member]
Amortization of intangible assets	$ 2	$ 2

Intangible Assets and Goodwill - Schedule of Estimated Future Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
2018	$ 228
2019	225
2020	222
2021	222
2022	222
Thereafter	1,741
Intangible assets	$ 2,860	$ 2,972

Intangible Assets and Goodwill - Schedule of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Balance beginning	$ 2,227	$ 2,466
Impairment of ImprimisRx TX		(239)
Balance ending	$ 2,227	$ 2,227

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Accounts payable	$ 3,241	$ 2,999
Deferred rent	388	412
Accrued interest (see Note 11)	256	116
Accrued exit fee for note payable (see Note 11)	800	667
Building lease liability		11
Total accounts payable and accrued expenses	4,685	4,205
Less: current portion	(3,885)	(3,538)
Non-current total accrued expenses	$ 800	$ 667

Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Jan. 22, 2016	May 11, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 27, 2016	Mar. 16, 2016
Principal amount of loan			$ 23,459
Loan due date			May 11, 2021
Liability of final fee included in accrued expenses			$ 800	$ 667
Fair value warrant adjustments			$ 982
Fair value of common stock			$ 2.08
Fair value of contractual term			7 years	5 years
Common stock volatility rate			113.50%	102.00%
Fair value of dividend rate			0.00%
Fair value of risk-free interest rate			1.77%	1.04%
Debt conversion price per share			$ 5.90			$ 5.90
Proceeds from convertible note				$ 2,772
Warrant exercise price per share			$ 1.915	$ 1.915		3.60
Amortization of debt discount			$ 978	$ 970
Loss on extinguishment			884	$ 1,966
Lender Warrants [Member]
Fair value warrant adjustments			$ 982
July 2017 [Member] \| Lender Warrants [Member]
Warrant exercise price per share			$ 3.08
Warrant to purchase of common stock			415,586
Warrant term			7 years
July 2017 [Member] \| London Inter-Bank Offered Rate [Member]
Loan bear interest			10.50%
August 2017 [Member] \| SWK Warrants [Member]
Warrant exercise price per share			$ 2.08
Warrant to purchase of common stock			615,386
SWK Loan Agreement [Member] \| July 2017 [Member]
Loan agreement term			5 years
Debt principal amount			$ 16,000
Repayment of debt			$ 750
Debt due date description			All amounts owed under the SWK Loan Agreement, including a final fee equal to 5% of the aggregate principal amount loaned thereunder, will be due and payable on July 19, 2022, or if certain revenue requirements are not met, July 19, 2021. The Company may elect to prepay all, but not less than all, of the amounts owed under the SWK Loan Agreement prior to the maturity date at any time after July 19, 2019. If certain revenue requirements are not met, the Company may be allowed to prepay the loan from July 19, 2018 to July 19, 2019, provided that a prepayment fee equal to 6% of the principal amount of the loan will also be due.
LSAF Loan [Member] \| July 2017 [Member]
Debt principal amount			$ 13,999
Convertible Note [Member]
Debt conversion price per share						3.60
Warrant exercise price per share						$ 3.60
Maximum [Member]
Common stock volatility rate				111.00%
Fair value of risk-free interest rate				1.70%
Maximum [Member] \| July 2017 [Member] \| London Inter-Bank Offered Rate [Member]
Loan bear interest			3.00%
Minimum [Member]
Common stock volatility rate				103.00%
Fair value of risk-free interest rate				1.22%
Minimum [Member] \| July 2017 [Member] \| London Inter-Bank Offered Rate [Member]
Loan bear interest			1.50%
Loan Agreement [Member]
Incurred expense debt			$ 1,282
Liability of final fee included in accrued expenses			$ 800
Loan Agreement [Member] \| Life Sciences Alternative Funding LLC [Member]
Principal amount of loan		$ 10,000
Loan bear interest		12.50%
Loans bear interest rate description		The term loan bore interest at a fixed per-annum rate of 12.5% and allowed for 2% of the interest to be paid-in-kind until December 2016. The Company was permitted to pay interest only until June 1, 2017.
Loan agreement term		20 months
Percentage of loan agreement final fee		5.00%
Loan due date		Jan. 01, 2019
Incurred expense debt		$ 1,066
Issuance of warrants to purchase maximum number of shares		125,000
Common stock exercise price per share		$ 7.85
Issuance of warrants to purchase of common stock expiration year		10 years
Fair value warrant adjustments		$ 840
Fair value of common stock		$ 7.97
Fair value of contractual term		10 years
Common stock volatility rate		109.00%
Fair value of dividend rate		0.00%
Fair value of risk-free interest rate		1.25%
Loan Agreement [Member] \| Life Sciences Alternative Funding LLC [Member] \| Maximum [Member]
Percentage of loan agreement prepayment fee		1.00%
Note Purchase Agreement [Member] \| Life Sciences Alternative Funding LLC [Member] \| 8.00% Convertible Senior Secured Note [Member]
Loan bear interest	8.00%
Loan due date	May 11, 2021
Incurred expense debt	$ 228
Debt principal amount	$ 3,000
Convertible note fixed per annum rate	8.00%
Convertible note description	The Company was permitted to redeem the Convertible Note prior to its maturity at any time on or after March 1, 2018 for cash purchase prices equal to 109% - 105% of the outstanding principal amount of the Convertible Note, depending on the date of redemption.
Debt conversion price per share	$ 5.90
Proceeds from convertible note	$ 3,000
Percentage of repurchase convertible note in cash is greater than outstanding principal amount	105.00%
Fair value of embedded conversion feature	$ 2,322
Exchange Agreement [Member] \| Life Sciences Alternative Funding LLC [Member]
Principal amount of loan					$ 3,000
Debt principal amount					$ 13,332
Warrant exercise price per share			$ 1.79
Amortization of debt discount			$ 1,966

Debt - Summary of Notes Payable (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
SWK note	$ 16,000
Less: Discounts on notes	(110)
Less: Current portion		$ 3,973
Long-term portion	14,008	$ 7,937
Notes Payable [Member]
SWK note	16,000
Less: Discounts on notes	(1,992)
Less: Current portion
Long-term portion	$ 14,008

Debt - Summary of Future Minimum Payments (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Debt Disclosure [Abstract]
2018	$ 1,947
2019	3,657
2020	3,440
2021	3,214
2022	11,201
Total minimum payments	23,459
Less: amount representing interest	(7,459)
Notes payable, gross	$ 16,000

Capital Lease Obligation (Details Narrative) - USD ($) $ in Thousands		12 Months Ended
	Aug. 09, 2016	Dec. 31, 2017	Dec. 31, 2016
Property and equipment purchase price		$ 772	$ 6,887
Debt discount amortization		978	970
Capital leases of equipment		2,070	2,070
Capital leases of accumulated depreciation		444	293
Lease Agreement [Member]
Property and equipment purchase price	$ 2,000	2,000
Lease monthly payments	$ 64
Lease future payment		300
Lease incurred expenses		$ 67
Capital lease future minimum payments percentage		16.80%
Debt discount amortization		$ 167	$ 90

Capital Lease Obligation - Schedule of Future Payment Under Capital Lease (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Leases [Abstract]
2018	$ 773
2019	751
Total minimum lease payments	1,524
Less: amount representing interest payments	(96)
Present value of future minimum lease payment	1,427
Less: unamortized discount	(110)
Present value of future net minimum lease payments	1,317
Less: current portion, net of unamortized discount	(598)	$ (458)
Capital lease obligation, net of current portion and unamortized discount	$ 720	$ 1,318

Stockholders' Equity and Stock-based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended								12 Months Ended
	Apr. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Oct. 31, 2016	May 31, 2016	Apr. 30, 2016	Mar. 31, 2016	Nov. 30, 2015	Dec. 31, 2017	Dec. 31, 2016	Mar. 16, 2016	Sep. 17, 2007
Common stock, shares authorized			90,000,000						90,000,000	90,000,000
Common stock, par value			$ 0.001						$ 0.001	$ 0.001
Proceeds from issuance of stock									$ 1,124	$ 212
Warrant exercise price per share			$ 1.915						$ 1.915	$ 1.915	$ 3.60
Shares issued upon exercise of stock options										$ 55
Number of shares issued investor relations related services, value										$ 302
Preferred stock, shares authorized			5,000,000						5,000,000	5,000,000
Preferred stock, par value			$ 0.001						$ 0.001	$ 0.001
Preferred stock, shares issued
Preferred stock, shares outstanding
Stock-based compensation									$ 2,943	$ 3,673
2007 Incentive Stock and Awards Plan [Member]
Maximum number of common stock issuance under the plan												2,000,000
Number of shares available for sales									1,997,500
Warrants [Member]
Warrant exercise price per share	$ 1.79
Proceeds from issuance of warrant	$ 179
Number of common stock issued for warrant exercises	100,000
Stock Option [Member]
Number of common stock issued for warrant exercises										15,000
Shares issued upon exercise of stock options										$ 55
Shares issued upon exercise of stock options, shares										15,000
Sale of stock price per share			$ 3.68							$ 3.68
Agent Warrant [Member] \| Maximum [Member]
Number of warrants issued for purchase of common stock			210,313							210,313
Non Employee Director [Member]
Issuance of restricted common stock, shares									62,892	63,450
Issuance of restricted common stock									$ 200	$ 250
Mark L. Baum [Member]
Number of restricted stock forfeit during period						1,050,000
Issuance of restricted common stock, shares						157,500
Mark L. Baum [Member] \| Maximum [Member]
Average stock price targets ranging						$ 15
Mark L. Baum [Member] \| Minimum [Member]
Average stock price targets ranging						$ 9
Restricted Stock Units [Member]
Number of shares vested during the period									137,067	80,245
Restricted Stock Units [Member] \| Non Employee Director [Member]
Number of shares vested during the period				16,076
Restricted Stock Units [Member] \| Mark L. Baum [Member]
Number of common stock issued			116,291
Number of shares vested during the period			200,000
Number of restricted stock issued			83,709
Payroll tax withholdings			$ 144
Restricted Stock Units [Member] \| Directors [Member]
Number of shares vested during the period									56,822	24,421
Restricted Stock [Member]
Number of shares issued investor relations related services		25,000
Number of shares issued investor relations related services, value		$ 60
Stock Option Plan [Member]
Shares issued upon exercise of stock options, shares
Closing price of common stock price per share									$ 1.70
Stock options granted with exercise price contractual terms									6 years 4 months 17 days
Stock options granted vesting terms									Vesting terms for options granted in 2017 and 2016 to employees and consultants typically included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; quarterly vesting over three years. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plan) and in the event of certain modifications to the option award agreement.	Vesting terms for options granted in 2017 and 2016 to employees and consultants typically included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; quarterly vesting over three years. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plan) and in the event of certain modifications to the option award agreement.
Forfeiture factor, percentage									10.00%
Expense expected to recognize over the weighted-average remaining vesting period									2 years 6 months
Stock-based compensation									$ 1,672	$ 2,159
Unrecognized compensation expense related to unvested stock options granted under the plan									$ 4,103
Stock Option Plan [Member] \| Maximum [Member]
Stock options granted with exercise price contractual terms									10 years	10 years
Stock Option Plan [Member] \| Minimum [Member]
Stock options granted with exercise price contractual terms									5 years	5 years
Unvested RSUs [Member]
Expense expected to recognize over the weighted-average remaining vesting period									10 months 25 days
Stock-based compensation									$ 1,211	$ 1,539
Unrecognized compensation expense related to unvested stock options granted under the plan									$ 1,326
Sales Agreement [Member]
Number of shares sold under the agreement									557,714	57,042
Proceeds from sale of common stock approximately									$ 1,124	$ 212
Sales commission and offering expenses									35	$ 20
Available future sales									$ 8,040
Securities Purchase Agreements [Member] \| Investor Warrants [Member]
Number of shares sold under the agreement			5,257,828
Sales commission and offering expenses			$ 852
Warrant exercise price per share			$ 1.79							$ 1.79
Proceeds from issuance of warrant			$ 9,217
Percentage of cash commission			7.50%
Securities Purchase Agreements [Member] \| Two Accredited Investors [Member]
Number of common stock issued		1,312,500
Price per share		$ 2.40
Net proceeds of registered offering		$ 2,940
Gross proceeds, percentage		6.00%
National Securities Corporation [Member] \| Underwriting Agreement [Member] \| Public Offering [Member]
Number of common stock issued							3,335,000
Price per share							$ 3.60
Proceeds from issuance of stock							$ 11,088
Cantor Fitzgerald & Co [Member] \| Sales Agreement [Member]
Cash commission, percentage								3.00%
PC [Member]
Number of shares issued for acquisitions					$ 75,000
Number of shares issued for acquisitions, shares					302

Stockholders' Equity and Stock-based Compensation - Schedule of Stock Option Plan Activity (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($) $ / shares shares
Weighted Avg. Exercise Price, Exercisable Ending Balance	$ 5.51
Stock Option Plan [Member]
Number of shares, Outstanding, Beginning balance \| shares	2,013,313
Number of shares, Options granted \| shares	538,000
Number of shares, Options exercised \| shares
Number of shares, Options cancelled/forfeit \| shares	(291,334)
Number of shares, Outstanding, Ending balance \| shares	2,259,979
Number of shares, Options exercisable \| shares	989,664
Number of shares, Options vested and expected to vest \| shares	2,137,854
Weighted Avg. Exercise Price, Outstanding, Beginning balance	$ 6.20
Weighted Avg. Exercise Price, Options granted	2.37
Weighted Avg. Exercise Price, Options exercised
Weighted Avg. Exercise Price, Options cancelled/forfeit	4.45
Weighted Avg. Exercise Price, Outstanding, Ending balance	5.51
Weighted Avg. Exercise Price, Exercisable Ending Balance	5.74
Weighted Avg. Exercise Price, Vested and expected to vest	$ 5.51
Weighted Avg. Remaining Contractual Life, Options outstanding	6 years 1 month 9 days
Weighted Avg. Remaining Contractual Life, Options exercisable	6 years 4 months 17 days
Weighted Avg. Remaining Contractual Life, Options vested and expected to vest	6 years 1 month 13 days
Aggregate Intrinsic Value, Options outstanding \| $	$ 1
Aggregate Intrinsic Value, Options exercisable \| $
Aggregate Intrinsic Value, Options vested and expected to vest \| $	$ 1

Stockholders' Equity and Stock-based Compensation - Schedule of Fair Value Assumption (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Options Granted to Employees [Member]
Weighted-average fair value of options granted	$ 2.04	$ 3.91
Expected volatility, minimum	112.00%	101.00%
Expected volatility, maximum	117.00%	112.00%
Risk-free interest rate, minimum	1.77%	1.07%
Risk-free interest rate, maximum	2.01%	1.70%
Dividend yield
Options Granted to Employees [Member] \| Minimum [Member]
Expected terms (in years)	5 years 9 months 22 days	5 years 9 months 22 days
Options Granted to Employees [Member] \| Maximum [Member]
Expected terms (in years)	6 years 1 month 9 days	6 years 1 month 9 days
Options Granted to Consultants [Member]
Weighted-average fair value of options granted		$ 6.18
Expected terms (in years)		10 years
Expected volatility		109.00%
Risk-free interest rate		1.06%
Dividend yield
Warrant Granted [Member]
Weighted-average fair value of options granted	$ 1.70	$ 2.88
Expected terms (in years)	7 years	5 years
Expected volatility	113.50%	106.00%
Risk-free interest rate	1.77%	0.79%
Dividend yield

Stockholders' Equity and Stock-based Compensation - Schedule of Shares Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2017 $ / shares shares
Range of Exercise Prices, minimum	$ 1.47
Range of Exercise Prices, maximum	$ 42.80
Number of Options Outstanding \| shares	2,259,979
Weighted Average Remaining Contractual Life in Years	6 years 1 month 9 days
Weighted Average Exercise Price	$ 5.51
Number Exercisable \| shares	989,664
Weighted Average Exercisable Exercise Price	$ 5.74
Range One [Member]
Range of Exercise Prices, minimum	1.47
Range of Exercise Prices, maximum	$ 2.60
Number of Options Outstanding \| shares	584,500
Weighted Average Remaining Contractual Life in Years	8 years 1 month 24 days
Weighted Average Exercise Price	$ 2.18
Number Exercisable \| shares	197,997
Weighted Average Exercisable Exercise Price	$ 2.35
Range Two [Member]
Range of Exercise Prices, minimum	3.20
Range of Exercise Prices, maximum	$ 4.50
Number of Options Outstanding \| shares	539,906
Weighted Average Remaining Contractual Life in Years	7 years 11 months 8 days
Weighted Average Exercise Price	$ 3.97
Number Exercisable \| shares	286,855
Weighted Average Exercisable Exercise Price	$ 3.99
Range Three [Member]
Range of Exercise Prices, minimum	5.49
Range of Exercise Prices, maximum	$ 6.36
Number of Options Outstanding \| shares	106,536
Weighted Average Remaining Contractual Life in Years	5 years 7 months 10 days
Weighted Average Exercise Price	$ 5.95
Number Exercisable \| shares	103,092
Weighted Average Exercisable Exercise Price	$ 5.97
Range Four [Member]
Range of Exercise Prices, minimum	6.64
Range of Exercise Prices, maximum	$ 8.99
Number of Options Outstanding \| shares	1,024,007
Weighted Average Remaining Contractual Life in Years	4 years 18 days
Weighted Average Exercise Price	$ 7.98
Number Exercisable \| shares	396,690
Weighted Average Exercisable Exercise Price	$ 8.18
Range Five [Member]
Range of Exercise Prices, minimum	$ 42.80
Number of Options Outstanding \| shares	5,030
Weighted Average Remaining Contractual Life in Years	2 years 7 months 13 days
Weighted Average Exercise Price	$ 42.80
Number Exercisable \| shares	5,030
Weighted Average Exercisable Exercise Price	$ 42.80

Stockholders' Equity and Stock-Based Compensation - Schedule of Market-based Vesting Conditions for Restricted Stock Units Granted (Details) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2017 shares
Tranche 1 [Member]
Number of shares vesting	230,000
Target share price description	9.00 or greater
Tranche 2 [Member]
Number of shares vesting	230,000
Target share price description	10.00 or greater
Tranche 3 [Member]
Number of shares vesting	230,000
Target share price description	12.00 or greater
Tranche 4 [Member]
Number of shares vesting	230,000
Target share price description	14.00 or greater
Tranche 5 [Member]
Number of shares vesting	287,500
Target share price description	15.00 or greater

Stockholders' Equity and Stock-Based Compensation - Schedule of Assumptions Used (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Market price		$ 3.98
Contractual terms (in years)	7 years	5 years
Expected volatility	113.50%	102.00%
Risk-free interest rate	1.77%	1.04%
Dividend yield	0.00%

Stockholders' Equity and Stock-based Compensation - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2017 $ / shares shares
Number of RSUs unvested, Outstanding, Beginning balance \| shares	1,292,876
Number of RSUs granted \| shares	62,892
Number of RSUs vested \| shares	(56,822)
Number RSUs cancelled/forfeit \| shares
Number of RSUs unvested, Outstanding, Ending balance \| shares	1,298,946
Weighted Average Grant Date Fair Value, Beginning balance \| $ / shares	$ 2.43
Weighted Average Grant Date Fair Value, RSUs granted \| $ / shares	3.18
Weighted Average Grant Date Fair Value, RSUs vested \| $ / shares	3.94
Weighted Average Grant Date Fair Value, RSUs cancelled/forfeit \| $ / shares
Weighted Average Grant Date Fair Value, Ending balance \| $ / shares	$ 2.42

Stockholders' Equity and Stock-based Compensation - Schedule of Stock Based Compensation Granted to Employees Directors Consultants (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Stock based compensation related to equity instruments granted to related parties	$ 2,943	$ 3,788
Employees [Member] \| Selling and Marketing [Member]
Stock based compensation related to equity instruments granted to related parties	449	498
Employees [Member] \| General and Administrative [Member]
Stock based compensation related to equity instruments granted to related parties	2,229	2,954
Directors [Member] \| General and Administrative [Member]
Stock based compensation related to equity instruments granted to related parties	205	221
Consultants [Member] \| Selling and Marketing [Member]
Stock based compensation related to equity instruments granted to related parties	60
Other [Member] \| General and Administrative [Member]
Stock based compensation related to equity instruments granted to related parties		$ 115

Stockholders' Equity and Stock-based Compensation - Schedule of Warrants Activity (Details) - Warrant [Member]	12 Months Ended
	Dec. 31, 2017 $ / shares shares
Number of shares, outstanding, beginning balance \| shares	5,748,829
Number of shares subject to warrants outstanding, granted \| shares	615,386
Number of shares subject to warrants outstanding, exercised \| shares	100,000
Number of shares subject to warrants outstanding, expired \| shares
Number of shares, outstanding and exercisable , ending balance \| shares	6,264,215
Weighted average remaining contractual life of the outstanding warrants in years	2 years 6 months 7 days
Weighted avg. Exercise price, outstanding, beginning balance \| $ / shares	$ 1.91
Weighted avg. Exercise price, granted \| $ / shares	2.08
Weighted avg. Exercise price, exercised \| $ / shares	1.79
Weighted avg. Exercise price, expired \| $ / shares
Weighted avg. Exercise price, outstanding and exercisable, ending balance \| $ / shares	$ 1.93

Stockholders' Equity and Stock-based Compensation - Schedule of Warrants Outstanding and Warrants Exercisable (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Mar. 16, 2016
Exercise Price	$ 1.915	$ 1.915	$ 3.60
Expiration Date	May 11, 2025
Warrant [Member]
Warrants Outstanding	6,264,215
Exercise Price	$ 1.93
Warrants Exercisable	6,264,215
Lender Warrants [Member]
Issue Date	May 11, 2015
Warrants Outstanding	125,000
Exercise Price	$ 1.79
Warrants Exercisable	125,000
Expiration Date	May 11, 2025
Underwriter Warrants [Member]
Issue Date	Feb. 07, 2013
Warrants Outstanding	55,688
Exercise Price	$ 5.25
Warrants Exercisable	55,688
Expiration Date	Feb. 07, 2018
Settlement Warrants [Member]
Issue Date	Aug. 16, 2016
Warrants Outstanding	40,000
Exercise Price	$ 3.75
Warrants Exercisable	40,000
Expiration Date	Aug. 16, 2021
Warrants Issued to Investor Relations Consultant [Member]
Issue Date	Jul. 19, 2013
Warrants Outstanding	60,000
Exercise Price	$ 8.50
Warrants Exercisable	60,000
Expiration Date	Jul. 19, 2018
Placement Agent Warrants [Member]
Issue Date	Dec. 27, 2016
Warrants Outstanding	210,313
Exercise Price	$ 1.79
Warrants Exercisable	210,313
Expiration Date	Dec. 27, 2019
PIPE Investor Warrants [Member]
Issue Date	Dec. 27, 2016
Warrants Outstanding	5,157,828
Exercise Price	$ 1.79
Warrants Exercisable	5,157,828
Expiration Date	Dec. 27, 2019
Lender Warrants One [Member]
Issue Date	Jul. 19, 2017
Warrants Outstanding	615,386
Exercise Price	$ 2.08
Warrants Exercisable	615,386
Expiration Date	Jul. 19, 2024

Derivative Instruments (Details Narrative) - $ / shares	12 Months Ended
Derivative Instruments (Details Narrative) - $ / shares	Dec. 31, 2017	Dec. 31, 2016	Mar. 16, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Debt conversion price per share	$ 5.90		$ 5.90
Warrant exercise price per share	$ 1.915	$ 1.915	$ 3.60
Warrants expiration date	May 11, 2025
Convertible note original maturity date	May 11, 2021

Derivative Instruments - Schedule of Derivative Liabilities at Fair Value (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Expected volatility	113.50%	102.00%
Risk-free interest rate	1.77%	1.04%
Dividend yield	0.00%
Minimum [Member]
Expected volatility		103.00%
Risk-free interest rate		1.22%
Maximum [Member]
Expected volatility		111.00%
Risk-free interest rate		1.70%

Derivative Instruments - Fair Value at Reconciliation of Measured Liabilities (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($)
Warrant Derivative Liability [Member]
Balance Beginning
Modification of warrant and reclassification from equity to liabilities	675
Change in fair value	(211)
Reclassification from liabilities to equity upon closing of public equity offering	(464)
Balance Ending
Embedded Conversion Feature Derivative Liability [Member]
Balance Beginning
Change in fair value	324
Reclassification from liabilities to equity upon closing of public equity offering	(2,646)
Embedded conversion feature in Convertible Note issued	2,322
Balance Ending

Income Taxes (Details Narrative) - USD ($)		12 Months Ended
Income Taxes (Details Narrative) - USD ($)	Dec. 27, 2017	Dec. 31, 2017	Dec. 31, 2016
Deferred tax asset valuation allowance	$ 8,059,000	$ 7,100	$ 7,200
Federal net operating loss carryforwards		62,899,000
Federal research and development tax credits		$ 354,000
Federal research and development tax credits expiration date		2026
State net operating loss carryforwards		$ 59,215,000
State net operating loss expiration date		2017
State research and development tax credits		$ 305,000
Unrecognized tax benefits
Corporate tax rate, percentage		(62.97%)	0.00%
Maximum [Member]
Corporate tax rate, percentage	35.00%
Minimum [Member]
Corporate tax rate, percentage	21.00%

Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Current: Federal
Current: State	5	8
Total current	5	8
Deferred: Federal	6,474	(5,623)
Deferred: State	(283)	(1,713)
Deferred: Change in valuation allowance	(7,126)	7,225
Total deferred	(935)	(111)
Income tax provision (benefit)	$ (935)	$ (111)

Income Taxes - Schedule of Income Tax Reconciliation (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
U.S. federal statutory tax rate	35.00%	35.00%
Benefit of lower tax brackets	(1.00%)	(1.00%)
State tax benefit, net	1.60%	0.08%
Research and development credits	0.00%	0.00%
Employee stock based compensation	0.84%	(1.47%)
Loss on debt conversion	(2.39%)	0.00%
Capitalization of Subsidiary	0.00%	0.00%
Change in Rate	(62.97%)	0.00%
Other	3.04%	(0.18%)
Valuation allowance	34.82%	(31.89%)
Effective income tax rate	7.26%	0.54%

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
NOL's	$ 17,405	$ 21,555
Depreciation and amortization	58	199
Other	351	398
Research & development credits	596	556
Deferred stock compensation	2,534	3,875
Basis Difference in Eton	(985)
Park stock purchase identifiable intangibles	(501)	(936)
Unrealized gain or loss on investments
Total deferred tax assets, net	19,458	25,647
Valuation allowance	(19,458)	(26,583)
Net deferred tax liabilities		$ (936)

Income Taxes - Schedule of Change in Unrecognized Tax Benefits (Details)	12 Months Ended
	Dec. 31, 2017 USD ($)
Income Tax Disclosure [Abstract]
UTB, Beginning balance
Additions for tax positions related to current year
Additions/(reductions) for tax positions related to prior years
UTB, Ending balance

Employee Savings Plan (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Retirement Benefits [Abstract]
Percentage of salary deposits in tax deferred investment account	100.00%
Percentage of contributions made by the company	4.00%
Contributions by the company	$ 288	$ 248

Commitments and Contingencies (Details Narrative) $ in Thousands			1 Months Ended			12 Months Ended
	May 31, 2017 USD ($) ft²	May 31, 2016 USD ($) shares	Apr. 30, 2017 USD ($)	Feb. 28, 2015 USD ($) ft²	Jan. 31, 2015 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Jul. 31, 2017 ft²	Aug. 31, 2016 shares	Apr. 30, 2016 USD ($)	Dec. 31, 2015 USD ($)	Jan. 02, 2015 ft²	May 31, 2014 ft²
Fair value of contingent acquisition obligation											$ 483
Gain loss on contingent acquisition							$ 81
Lease agreement for office space (square feet) \| ft²	10,200
Operating lease, monthly rental						$ 649	668
Operating lease, rent increase percentage	3.00%
Number of warrants issued \| shares									40,000
Litigation settlement costs						450
Insurance claim in other income							861
Accrued royalty expenses						$ 108	3
Pharmacy Creations, LLC [Member]
Payment of cash		$ 100
Number of common stock shares issued for maximum exceeds from revenue \| shares		75,000
Issuance of common stock to settle contingent acquisition obligation		$ 302
Lease Agreement [Member]
Lease agreement for office space (square feet) \| ft²				8,600				7,000					7,565
Operating lease, monthly rental				$ 15
Operating lease, rent increase percentage				3.75%
Operating lease expiry				Jul. 31, 2022		Dec. 31, 2021
Amended Lease Agreement [Member]
Lease agreement for office space (square feet) \| ft²	2,635
Operating lease, monthly rental	$ 29
Commercial Lease Agreement [Member]
Lease agreement for office space (square feet) \| ft²												4,500
Operating lease, monthly rental					$ 10
Operating lease, rent increase percentage												3.00%
Operating lease expiry					Dec. 31, 2020
License Agreement [Member] \| Urigen Pharmaceuticals, Inc [Member]
Unpaid royalties										$ 698
Gain on settlement							$ 551
License Agreement [Member] \| Richard L. Lindstrom, M.D [Member]
Royalty payments						$ 19
License Agreement [Member] \| Richard L. Lindstrom, M.D [Member] \| Initial Payment [Member]
Royalty payments			$ 50
License Agreement [Member] \| Richard L. Lindstrom, M.D [Member] \| Second Payment [Member]
Royalty payments			50
Net sales			50
License Agreement [Member] \| Richard L. Lindstrom, M.D [Member] \| Final Payment [Member]
Royalty payments			50			50
Net sales			$ 100
Klarity License Agreement [Member] \| Richard L. Lindstrom, M.D [Member]
Royalty payment description			the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% to 6% of net sales, dependent upon the final formulation of the Klarity Product sold.
Sales and Marketing Agreements [Member]
Commission expense incurred						$ 183
Sales and Marketing Agreements [Member] \| Minimum [Member]
Commission payments, percentage						10.00%
Sales and Marketing Agreements [Member] \| Maximum [Member]
Commission payments, percentage						14.00%

Commitments and Contingencies - Schedule of Future Payments Under Leases (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2018	$ 697
2019	697
2020	697
2021	571
2022	111
Total	$ 2,773

Segment Information and Concentrations (Details Narrative) - Segment	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Segment Reporting [Abstract]
Number of reportable segment	1
Maximum percentage of sales derived from single customer	10.00%	10.00%
Percentage of drug and chemical purchases from three main suppliers	68.00%	69.00%

Subsequent Events (Details Narrative) - USD ($) $ in Thousands	1 Months Ended			12 Months Ended
	Mar. 31, 2018	Feb. 28, 2018	Jan. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Proceeds from common stock				$ 1,124	$ 212
Sales Agreement [Member]
Number of common stock sold				557,714	57,042
Subsequent Event [Member] \| Andrew R. Boll [Member]
Number of common stock issued		30,000
Subsequent Event [Member] \| John P Saharek [Member]
Number of common stock issued		30,000
Subsequent Event [Member] \| Restricted Common Stock [Member]
Number of common stock issued	35,427		25,273
Royalty payment	$ 64		$ 44
Subsequent Event [Member] \| Sales Agreement [Member]
Number of common stock sold			33,800
Proceeds from common stock			$ 57